Compositions, formulations and methods for skin treatment
By administering a compound composition of a specific structure to the subject, problems in the prior art are solved that are difficult to prevent or treat skin conditions, and effective skin treatment and cosmetic effects are achieved, including reducing wrinkles and hair problems.
Patent Information
- Application Number
- CN202380025764.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-07
- Filing Date
- 2023-01-06
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is difficult to effectively prevent or treat skin conditions, conditions or diseases, especially skin problems caused by long-term use of chemicals.
Provided a method of administering to a subject in need thereof a compound composition comprising a specific structure, including a formula (I), (II), (III), (IV), (V), (VI) or (VII) A compound or a salt thereof, used to prevent or treat skin conditions, disorders or diseases. These compounds or salts thereof may be selected from the structures or subsets thereof as shown in Tables 1-8 and may be used in pharmaceutical or cosmetic compositions.
This method can effectively prevent or treat skin conditions, conditions or diseases, including hair loss or thinning, improve skin firmness, increase collagen production, reduce wrinkles, and provide skin moisturizing and protective effects.
Smart Images

Figure CN119072466A_ABST
Abstract
Description
[0001] Cross-references
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 297,413, filed on January 7, 2022, the entire contents of which are incorporated herein by reference. Summary of the invention
[0003] Skin conditions, disorders or diseases (whether or not a diagnosis of the skin condition, disorder or disease has been made) are a common problem that occurs naturally or is chemically promoted, for example, by the long-term use of certain chemicals (e.g., commercial products or therapeutic drugs).
[0004] The present disclosure provides a method for preventing or treating a skin condition, disorder or disease (whether or not a diagnosis of the skin condition, disorder or disease has been made), the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (I), (II), (III), (IV), (V), (VI) or (VII). These compounds or their salts may be selected from those shown in Tables 1-8, or any subset thereof.
[0005] Provided herein is a method for preventing or treating a skin condition, disorder or disease. In some embodiments, the method comprises administering to a subject in need thereof a composition comprising a compound having a structure of Formula (V) or a salt thereof:
[0006]
[0007] in:
[0008] Y 1 O, S or NR 1 , where R 1 is H, alkyl or haloalkyl;
[0009] R 2 is selected from the group consisting of H, alkyl, haloalkyl, alkenyl, haloalkenyl, aryl, and aralkyl; and
[0010] R 3 Selected from H, alkyl, haloalkyl, -(CH2) m1 -OR a1 、-(CH2) m2 -O-(CH2) m3 -OR a2 、-(CH2) m4 -NR b1 R b2 、(CH2) m5 -C(O)OR c ,in:
[0011] Ra1 , R a2 , R b1 , R b2 and R c are each independently selected from H, alkyl and haloalkyl; and
[0012] m1, m2, m3, m4 and m5 are each independently selected from 1, 2, 3 and 4.
[0013] In some embodiments, Y 1 is O or S. In some embodiments, Y 1 is O. In some embodiments, R a1 , R a2 , R b1 , R b2 and R c Each is independently C1-C6 alkyl, such as C1-C3 alkyl. a1 , R a2 , R b1 , R b2 and R c Each is independently C1 alkyl or C2 alkyl. In some embodiments, m1, m2, m3 and m4 are each independently 2 or 3. In some embodiments, m5 is 1. In some embodiments, R 2 It's H.
[0014] In some embodiments, the compound of formula (V) or a salt thereof is selected from:
[0015]
[0016] and salts of any of them.
[0017] Provided herein is a method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having formula (IV) or a salt thereof:
[0018]
[0019] in:
[0020] R 1 is selected from alkyl or heterocycloalkyl, wherein R 1 The alkyl or heterocycloalkyl of is optionally independently selected from heterocycloalkyl, -C(O)NR x1 R x2 , alkoxy, -(C1-C3 alkylene)-C(O)OR y1 、-C(O)OR y2 AND-OR zsubstituted with one or more substituents; wherein:
[0021] R x1 , R x2 , R y1 , R y2 and R z are each independently selected from H, alkyl and haloalkyl;
[0022] R A is H or alkyl;
[0023] X is -O-, -S- or -NR B -; R B is H, alkyl or haloalkyl;
[0024] R 2 and R 3 are each independently selected from H, linear C1-C6 alkyl, branched C1-C6 alkyl; or alternatively, R 2 and R 3 together with the atoms to which they are attached to form a C4-C6 cycloalkyl or aryl group, wherein the cycloalkyl or aryl group is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl; and
[0025] The dashed lines indicate the presence of single or double bonds.
[0026] In some embodiments, the compound of formula (IV) has the structural formula:
[0027]
[0028] In some embodiments, the compound of formula (IV) has the structural formula:
[0029]
[0030] In some embodiments, the compound of formula (IV) has the structural formula:
[0031]
[0032] In some embodiments, the compound of formula (IV) has the structural formula:
[0033]
[0034] In some embodiments, R 2 and R 3 Each is independently selected from C1-C6 alkyl.
[0035] In some embodiments, R 2 and R 3Together with the atoms to which they are attached to form a C4-C6 cycloalkyl group optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl.
[0036] In some embodiments, R 2 and R 3 Together with the atoms to which they are attached to form a cyclohexyl group, the cyclohexyl group is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl.
[0037] In some embodiments, R 2 and R 3 Together with the atoms to which they are attached, they form C 5-8 Aryl, the C 5-8 The aryl group is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl.
[0038] In some embodiments, R 2 and R 3 Together with the atoms to which they are attached to form a phenyl group, the phenyl group is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl.
[0039] In some embodiments, R A It's H.
[0040] In some embodiments, X is -O-. In some embodiments, X is -NR B -, optionally, wherein R B It's H.
[0041] In some embodiments, R 1 Selected from: -(CH2) a C(O)OH, -(CH2) a OCH3, -(CH2) a CH(OH)CH3, Where: a is 0, 1, 2 or 3.
[0042] In some embodiments, R 1 Selected from: -CH2C(O)OH, -(CH2)2OCH3, -CH2CH(OH)CH3,
[0043] In some embodiments, R x1 and R x2 Each is independently a C1-C6 alkyl group.
[0044] In some embodiments, R x1 and R x2 Each is independently a C1-C3 alkyl group.
[0045] In some embodiments, R y1 It's H.
[0046] In some embodiments, R y2 It's H.
[0047] In some embodiments, R z It's H.
[0048] In some embodiments, the compound of formula (IV) or a salt thereof is selected from:
[0049]
[0050] and salts of any of them.
[0051] Provided herein is a method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having formula (VII) or a salt thereof:
[0052]
[0053] in:
[0054] A is selected from O, NH, S;
[0055] R 1 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 2-10 Alkynyl, C 3-12 Carbocyclic and 3- to 12-membered heterocyclic rings;
[0056] R 2 is selected from a 6- to 10-membered heterocyclic ring, wherein the 6- to 10-membered heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, -OR 11 、-SR 11 , -NO2, =O, =NH, -CN, -C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2.-NR 11 S(O)2R 11 、-C(O)N(R 11 )2、-N(R11 )C(O)R 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )C(O)OR 11 、-S(O)2(R 11 )、-S(O)2N(R 11 2. C 1-10 Alkyl, C3-C 12 Carbocyclic and 5- to 12-membered heterocyclic rings;
[0057] n is selected from 1, 2, 3, 4, 5 and 6;
[0058] Each R 11 is independently selected at each occurrence from hydrogen; C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-12 carbocyclic rings, each of which is optionally substituted with one or more substituents selected from 3- to 6-membered heterocyclic rings.
[0059] In some embodiments, A is O.
[0060] In some embodiments, R 1 It is C 1-6 In some embodiments, R 1 It is a C1 alkyl group.
[0061] In some embodiments, n is selected from 1 and 3. In some embodiments, n is 1. In some embodiments, n is 3.
[0062] In some embodiments, R 2 The 6- to 10-membered heterocyclic ring is selected from pyran, pyridine, piperidine, imidazole, thiazole, dioxane, morpholine, pyrimidine, benzimidazole, piperazine, thiadiazine, oxepane, thiene, azoctatetraene, indole, isoindole, indolizine, quinoline, isoquinoline, purine, carbazole and dibesofuran.
[0063] In some embodiments, R 2 is selected from benzimidazole and piperazine. 2 yes In some embodiments, R 2 is piperazine. In some embodiments, piperazine is optionally independently selected from ═O and —C(O)R 11 In some embodiments, R 11 is C substituted by one or more substituents selected from 3- to 6-membered heterocyclic rings 1-6In some embodiments, C 1-6 Alkyl is C1 alkyl or C2 alkyl. In some embodiments, the 3- to 6-membered heterocyclic ring is
[0064] In some embodiments, each R 2 Selected from:
[0065] In some embodiments, the compound of formula (VII) or a salt thereof is selected from:
[0066] and salts of any of them.
[0067] Also provided herein is a method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound of formula (III) or a salt thereof:
[0068]
[0069] in:
[0070] L 1 , L 2 and L 3 Each independently selected from a bond, a straight chain C 1-6 Alkyl or branched C 1-6 alkyl;
[0071] A is N-amido, -NH-C(O)- or -C(O)-NH-;
[0072] Ring B is selected from C 4-6 Cycloalkyl, 5- or 6-membered heterocyclic group, C 5-8 Aryl, heteroaryl and aralkyl groups;
[0073] R x and R y Each is independently selected from halogen, alkyl, haloalkyl, alkenyl, haloalkenyl, hydroxy, alkoxy, haloalkoxy, nitro, -NH2, alkylamino, dialkylamino and haloalkylamino;
[0074] m is 0, 1, or 2; and
[0075] n is 0 or 1.
[0076] In some embodiments, Ring B is selected from C 5-8 In some embodiments, ring B is selected from C 5-8 Aryl and Heteroaryl. In some embodiments, C5-8 aryl is phenyl and heteroaryl is imidazolyl.
[0077] In some embodiments, R x is C1-C3 alkoxy. x It is -OCH3.
[0078] In some embodiments, Ring B is In some embodiments, Ring B is
[0079] In some embodiments, m is 0 or 1. In some embodiments, n is 0.
[0080] In some embodiments, the compound of formula (III) or a salt thereof is selected from:
[0081]
[0082]
[0083] and salts of any of them.
[0084] Provided herein is a method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having formula (II) or a salt thereof:
[0085]
[0086] in:
[0087] R 1a and R 1b are independently selected from H, alkyl, haloalkyl, alkenyl, haloalkenyl, C 5-8 Aryl and aralkyl groups;
[0088] R x Each is independently selected from halogen, alkyl, haloalkyl, alkenyl, haloalkenyl, -OH, alkoxy, haloalkoxy, nitro, -NH2, alkylamino, dialkylamino and haloalkylamino;
[0089] p is 1, 2, or 3;
[0090] q is 0, 1, or 2;
[0091] R 2 is selected from the group consisting of H, alkyl, alkenyl, haloalkyl, haloalkenyl, nitro, -NH2, alkylamino, dialkylamino, alkyl-dialkylamino, and haloalkylamino; and
[0092] R 3 is selected from H, alkyl and haloalkyl.
[0093] In some embodiments, R 1a and R 1b Independently selected from H and C 1-6 In some embodiments, R 1a and R 1b It's H.
[0094] In some embodiments, R x is C1 to C6 alkoxy. In some embodiments, Rx is -OCH3.
[0095] In some embodiments, q is 0 or 1. In some embodiments, p is 1.
[0096] In some embodiments, R 2 It is C 1-6 In some embodiments, R 2 is selected from methyl, ethyl, propyl, butyl, isopropyl, isobutyl and
[0097] In some embodiments, R 3 It's H.
[0098] In some embodiments, the compound of formula (II) or a salt thereof is selected from:
[0099] and salts of any of them.
[0100] Provided herein is a method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having formula (I) or a salt thereof:
[0101]
[0102] in:
[0103] R 1a and R 1b independently selected from H, alkyl and haloalkyl;
[0104] R 3 is selected from cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl or aralkyl is optionally substituted with one or more substituents independently selected from halogen, alkyl, alkoxy and haloalkoxy;
[0105] R xEach is independently selected from halogen, alkyl, haloalkyl, alkenyl, haloalkenyl, -OH, alkoxy, haloalkoxy, -NH2, alkylamino, dialkylamino and haloalkylamino;
[0106] p is 1, 2, or 3;
[0107] q is 0, 1, or 2; and
[0108] Q is selected from O, S and NR 2 , where R 2 is selected from the group consisting of H, alkyl, alkenyl, haloalkyl, haloalkenyl, nitro, -NH2, alkylamino, dialkylamino and haloalkylamino.
[0109] In some embodiments, Q is NR 2 .
[0110] In some embodiments, R 2 Selected from amino, C 1-3 Alkyl and C 1-3 Alkenyl.
[0111] In some embodiments, R 1a and R 1b Independently selected from H, C 1-6 Alkyl and C 1-6 In some embodiments, R 1a and R 1b Independently selected from H, C 1-4 Alkyl and C 1-4 In some embodiments, R 1a and R 1b It's H.
[0112] In some embodiments, R 3 Selected from C 4-6 In some embodiments, R 3 yes In some embodiments, R 3 yes
[0113] In some embodiments, q is 0.
[0114] In some embodiments, the compound of formula (I) or a salt thereof is selected from:
[0115]
[0116] and salts of any of them.
[0117] Provided herein is a method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having formula (VI) or a salt thereof:
[0118]
[0119] in:
[0120] R a are each independently selected from alkyl, haloalkyl, alkenyl, haloalkenyl and alkoxy;
[0121] R 1 and R 2 One of is H or alkyl;
[0122] R 1 and R 2 The other one is selected from H, alkyl, alkoxy, -(C1-C6 alkylene)-C(O)NR x1 -(C1-C6 alkylene)-aryl and -(C1-C6 alkylene)-C(O)NR x2 -(C1-C6 alkyl), where R x1 and R x2 are each independently H, alkyl or haloalkyl; and
[0123] p is 0, 1 or 2.
[0124] In some embodiments, R x1 is H. In some embodiments, R x2 It's H.
[0125] In some embodiments, R 1 and R 2 One of is H. In some embodiments, R 1 and R 2 The other one is selected from C1-C6 alkyl, In some embodiments, R 1 and R 2 The other one of which is selected from isopropyl,
[0126] In some embodiments, p is 0. In some embodiments, p is 1.
[0127] In some embodiments, R a is C1-C6 alkyl or C1-C6 alkoxy. a is C1-C3 alkyl or C1-C3 alkoxy. aIt is -CH3 or -OCH3.
[0128] In some embodiments, the compound of formula (VI) or a salt thereof is selected from: and salts of any of them.
[0129] Provided herein is a method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound selected from the group consisting of:
[0130]
[0131]
[0132]
[0133] and salts of any of them.
[0134] In some embodiments, the subject has been diagnosed with a skin condition, disorder or disease. In some embodiments, the subject has not been diagnosed with a skin condition, disorder or disease.
[0135] In some embodiments, the composition is a pharmaceutical composition.In some embodiments, the composition further comprises at least one additive selected from a pharmaceutically acceptable carrier, excipient, adjuvant, diluent, and a combination thereof.
[0136] In some embodiments, the composition is a cosmetic composition.In some embodiments, the composition further comprises at least one additive selected from the group consisting of cosmetically acceptable carriers, excipients, adjuvants, diluents, and combinations thereof.
[0137] In some embodiments, the composition is formulated as a toner, cream, emulsion, lotion, ointment, paste, gel, suspension, serum, oil, spray, lotion, mousse, or mist.
[0138] In some embodiments, the administering comprises applying the composition to a skin area of the subject. In some embodiments, the skin area comprises facial skin, elbow skin, neck skin, hand skin, periarticular skin, or a combination thereof. In some embodiments, facial skin comprises the skin of the forehead, temples, zygomatic region, nasolabial folds, marionette lines, chin, mandible, midface, preauricular region, periorbital depression, cheeks, jawline, lips, or any combination thereof.
[0139] In some embodiments, the method prevents or reduces wrinkles or fine lines. In some embodiments, the method increases skin firmness. In some embodiments, the method moisturizes / hydrates the skin. In some embodiments, the method increases skin collagen production or collagen depositing cell proliferation. In some embodiments, the method increases fibroblast proliferation.
[0140] Other aspects and advantages of the present disclosure will become apparent to those skilled in the art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be appreciated, the present disclosure is capable of implementing other and different embodiments, and its several details are capable of being modified in various obvious aspects, all without departing from the present disclosure. Therefore, the drawings and descriptions are to be regarded as illustrative rather than restrictive.
[0141] Incorporation by reference
[0142] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS
[0143] The novel features of the present invention are particularly set forth in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by referring to the following detailed description and accompanying drawings (also referred to herein as "figures") which set forth illustrative embodiments in which the principles of the invention are utilized, wherein:
[0144] Figure 1 An example depiction of a dose response curve from Compound 1-1 is shown.
[0145] Figure 2 An example depiction of a dose response curve from Compound II-1 is shown.
[0146] Figure 3 An example depiction of a dose response curve from Compound IV-2 is shown.
[0147] Figure 4 An example depiction of a dose response curve from Compound V-1 is shown.
[0148] Figure 5A-5E Exemplary compounds that did not exhibit genotoxic transformation potential are shown. Figure 5A An example graph of TK.6 cells treated with compound V-1 is shown. The genotoxic alkylating agent methyl methanesulfonate was used as a positive control for the micronucleus assay. Figure 5B Shown is the quantification of the TK.6 micronucleus assay following treatment with a range of concentrations of various example compounds. Figure 5CShown are normalized β-galactosidase activity (as quantified via absorbance) from the SOS chromogenic assay using varying concentrations of genotoxin (4-NQ; 4-nitroquinoline-1-oxide) and example compounds. The SOS chromogenic assay is a bacteria-based genotoxicity test. Figure 5D Normalized reactive oxygen species (ROS) activity of human dermal papilla cells treated with 5 μg / mL of example compounds for 24 hours relative to vehicle control (0.1% v / v DMSO) is shown. All example compounds tested induced small changes in ROS activity compared to baseline vehicle control. Figure 5E Shown are normalized caspase 3 / 7 activities in HepG2 cells, an immortalized hepatic cell line used to study apoptosis induced by small molecules.
[0149] Figure 6A-6E Exemplary compounds that did not exhibit any skin sensitization potential or immunogenicity are shown. Fig. 6A Normalized ARE-luciferase activity using a range of concentrations of the sensitizing compound (cinnamaldehyde) and the example compounds is shown. Figure 6B An in vitro dendritic cell sensitization assay is described. Dendritic cell activation is widely correlated with downstream immunogenicity. Figure 6C-Figure 6E is an example diagram showing changes in HLA-DR expression. Figure 6C )、PDL-1( Fig.6D ) and CD141( Fig. 6E ) expression was quantified via mean fluorescence intensity (MFI) after administration of exemplary compounds.
[0150] Figure 7 Example photographs of subjects in a clinical study are shown. DETAILED DESCRIPTION
[0151] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Without departing from the present invention, those skilled in the art will now conceive of many variations, changes and replacements. It should be understood that the various alternatives of the embodiments of the present invention described herein can be used to practice the present invention. The following claims are intended to define the scope of the present invention, and thus cover methods and structures and their equivalents within the scope of these claims.
[0152] In certain aspects, the present disclosure provides compositions and compounds that can be used to prevent or treat hair loss or thinning hair. The compound may include the structure of a compound of formula (I), (II), (III), (IV), (V), (VI) or (VII) or a salt thereof. The compound may include the structure of Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7 or Table 8 or a salt thereof. The compound may be included in a pharmaceutical or cosmetic composition or formulation.
[0153] In certain aspects, the present disclosure provides a method for preventing or treating hair loss or thinning hair (regardless of whether a diagnosis of hair loss or thinning hair has been made). Some aspects include a method for preventing or treating a skin condition, disorder or disease. Some embodiments include a method for treating a skin condition, disorder or disease. The skin condition, disorder or disease may be on an object. The object may have been diagnosed with a skin condition, disorder or disease or may not have been diagnosed with a skin condition, disorder or disease. The method may include administering to an object in need thereof a composition comprising a compound having a structure of formula (I), (II), (III), (IV), (V), (VI) or (VII) or a salt thereof. The method may include administering to an object in need thereof a composition comprising a compound having a structure in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7 or Table 8 or a salt thereof.
[0154] definition
[0155] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0156] As used in the specification and claims, the singular form "a," "an," and "the" include plural references unless the context clearly dictates otherwise.
[0157] Whenever the term "at least", "greater than", or "greater than or equal to" precedes the first value in a sequence of two or more values, the term "at least", "greater than", or "greater than or equal to" applies to each value in the sequence of values. For example, greater than or equal to 1, 2, or 3 is equivalent to greater than or equal to 1, greater than or equal to 2, or greater than or equal to 3.
[0158] Whenever the term "not greater than," "less than," or "less than or equal to" precedes the first value in a sequence of two or more values, the term "not greater than," "less than," or "less than or equal to" applies to every value in the sequence of values. For example, less than or equal to 3, 2, or 1 is equivalent to less than or equal to 3, less than or equal to 2, or less than or equal to 1.
[0159] The expressions "at least one of A and B" and "at least one of A or B" may be interpreted as meaning at least A, at least B, or at least A and B (i.e., a set containing A and B, which set may include one or more additional elements). The term "A and / or B" may be interpreted as meaning only A, only B, or both A and B.
[0160] The expressions "at least about A, B, and C" and "at least about A, B, or C" may be interpreted to mean at least about A, at least about B, or at least about C. The expressions "at most about A, B, and C" and "at most about A, B, or C" may be interpreted to mean at most about A, at most about B, or at most about C.
[0161] The expression "between about A and B, C and D, and E and F" may be interpreted as meaning between about A and about B, between about C and about D, and between about E and about F. The expression "between about A and B, C and D, or E and F" may be interpreted as meaning between about A and about B, between about C and about D, or between about E and about F.
[0162] The expression "about A to B and C to D" may be interpreted as meaning between about A and about B and between about C and about D. The expression "about A to B or C to D" may be interpreted as meaning between about A and about B or between about C and about D.
[0163] The term “exemplary” as used herein means “serving as an example, instance, or illustration.” Any implementation described herein as “exemplary” is not to be construed as preferred or advantageous over other implementations.
[0164] The term "C x-y " or "C x -C y " when used in combination with a chemical moiety such as alkyl, alkenyl or alkynyl, is intended to include groups containing x to y carbons in the chain. For example, the term "C 1-6 "Alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups, including straight chain alkyl and branched chain alkyl groups containing 1 to 6 carbon atoms.
[0165] The term "C x-y "Alkenyl" and "C x-y "Alkynyl" refers to a substituted or unsubstituted unsaturated aliphatic group analogous in length and possible substitution to the alkyls described above, but containing at least one double or triple bond respectively.
[0166] The term "aryl" refers to an aromatic monocyclic or aromatic polycyclic hydrocarbon ring system. An aromatic monocyclic or aromatic polycyclic hydrocarbon ring system contains only hydrogen and carbon and 5 to 18 carbon atoms, wherein at least one ring of the ring system is aromatic, i.e., contains a cyclic delocalized (4n+2) π-electron system according to the Hückel theory. Ring systems from which aryl groups are derived include, but are not limited to, radicals such as benzene, fluorene, indane, indene, tetralin and naphthalene.
[0167] The term "cycloalkyl" refers to a saturated ring in which each atom of the ring is carbon. Cycloalkyl can include monocycles and polycycles, such as 3- to 10-membered monocycles, 5- to 12-membered bicycles, spirobicycles, and 5- to 12-membered bridged rings. In certain embodiments, cycloalkyl contains 3 to 10 carbon atoms. In other embodiments, cycloalkyl contains 5 to 7 carbon atoms. Cycloalkyl can be attached to the rest of the molecule by a single bond. Examples of monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
[0168] The term "halo" or, alternatively, "halogen" or "halide" means fluoro, chloro, bromo or iodo. In some embodiments, halo is fluoro, chloro or bromo.
[0169] The term "haloalkyl" refers to an alkyl group as defined above substituted with one or more halo groups, for example, trifluoromethyl, dichloromethyl, bromomethyl, 2,2,2-trifluoroethyl, 1-chloromethyl-2-fluoroethyl, etc. In some embodiments, the alkyl portion of the haloalkyl group is optionally further substituted as described herein.
[0170] As used herein, the term "heterocycle" refers to a saturated, unsaturated or aromatic ring containing one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B and S atoms. Heterocycles include 3- to 10-membered monocycles, 6- to 12-membered bicyclic rings, 5- to 12-membered spiral bicyclic rings and 5- to 12-membered bridged rings. Bicyclic heterocycles include any combination of saturated, unsaturated and aromatic bicyclic rings, as long as valence permits. In exemplary embodiments, aromatic rings, such as pyridyl, can be fused with saturated or unsaturated rings, such as cyclohexane, cyclopentane, morpholine, piperidine or cyclohexene. Bicyclic heterocycles include any combination of ring sizes, such as 4-5 fused ring systems, 5-5 fused ring systems, 5-6 fused ring systems, 6-6 fused ring systems, 5-7 fused ring systems, 6-7 fused ring systems, 5-8 fused ring systems and 6-8 fused ring systems. Bicyclic heterocycles further include spiro bicycles, for example, 5- to 12-membered spiro bicycles.
[0171] The term "heterocycloalkyl" refers to a stable 3- to 12-membered non-aromatic ring group containing 2 to 12 carbon atoms and at least one heteroatom, wherein each heteroatom can be selected from N, O, Si, P, B and S atoms. Heterocycloalkyl can be selected from monocyclic or bicyclic and fused or bridged ring systems. The heteroatoms in the heterocycloalkyl are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocycloalkyl is partially or fully saturated. When valence permits, the heterocycloalkyl is attached to the rest of the molecule through any atom of the heterocycloalkyl (such as any carbon atom or nitrogen atom of the heterocycloalkyl). Examples of heterocycloalkyl groups include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidine, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl.
[0172] The term "heteroaryl" refers to a group derived from a 5- to 18-membered aromatic ring group, including 2 to 17 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur. As used herein, a heteroaryl is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein at least one ring in the ring system is aromatic, i.e., according to the Hückel theory, it contains a cyclic delocalized (4n+2) π-electron system. Heteroaryls include fused rings or bridged ring systems. The heteroatoms in the heteroaryl are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl is attached to the rest of the molecule through any atom of the ring. Examples of heteroaryls include, but are not limited to, azepine, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl and thiophenyl (i.e., thienyl).
[0173] The term "substituted" refers to a substituent having a substituent group that replaces one or more carbons or replaceable heteroatoms (e.g., NH or NH2 of a compound) on hydrogen. It should be understood that "replacement" or "replacement with..." includes implicit conditions, i.e., such substitutions meet the allowed valences of the substituted atoms and substituent groups, and the substitutions produce stable compounds, i.e., the compounds do not spontaneously transform, such as by rearrangement, cyclization, elimination, etc. In certain embodiments, substituted refers to a substituent group having a substituent group that replaces two hydrogen atoms on the same carbon atom, such as replacing two hydrogen atoms on a single carbon with an oxo, imino or thio group. As used herein, the term "substituted" is intended to include all allowed substituent groups of organic compounds. In a broad sense, allowable substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. For suitable organic compounds, allowable substituents can be one or more and are the same or different.
[0174] In some embodiments, the substituents may include any of the substituents described herein, for example, halogen, hydroxy, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R bb -OR aa , -R bb -OC(O)-R aa , -R bb -OC(O)-OR aa , -R bb -OC(O)-N(R aa )2. -R bb -N(R aa )2. -R bb -C(O)R aa , -R bb -C(O)OR aa , -R bb -C(O)N(R aa )2. -R bb -OR cc -C(O)N(R aa )2. -R bb -N(R aa )C(O)OR aa , -R bb -N(R aa )C(O)R aa , -R bb -N(R aa )S(O) t R aa (where t is 1 or 2), -R bb -S(O)t R aa (where t is 1 or 2), -R bb -S(O) t OR aa (where t is 1 or 2) and -R bb -S(O) t N(R aa )2 (wherein t is 1 or 2); and alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl, any of which may be optionally substituted by alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R bb -OR aa , -R bb -OC(O)-R aa , -R bb -OC(O)-OR aa , -R bb -OC(O)-N(R aa )2. -R bb -N(R aa )2. -R bb -C(O)R aa , -R bb -C(O)OR aa , -R bb -C(O)N(R aa )2. -R bb -OR cc -C(O)N(R aa )2. -R bb -N(R aa )C(O)OR aa , -R bb -N(R aa )C(O)R aa , -R bb -N(R aa )S(O) t R aa (where t is 1 or 2), -R bb -S(O) t R aa (where t is 1 or 2), -R bb -S(O) t OR aa (where t is 1 or 2) and -R bb -S(O) t N(Raa )2 (wherein t is 1 or 2); wherein each R aa is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, wherein each R aa , where valence permits, may be optionally replaced by alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R bb -OR aa , -R bb -OC(O)-R aa , -R bb -OC(O)-OR aa , -R bb -OC(O)-N(R aa )2. -R bb -N(R aa )2. -R bb -C(O)R aa , -R bb -C(O)OR aa , -R bb -C(O)N(R aa )2. -R bb -OR cc -C(O)N(R aa )2. -R bb -N(R aa )C(O)OR aa , -R bb -N(R aa )C(O)R aa , -R bb -N(R aa )S(O) t R aa (where t is 1 or 2), -R bb -S(O) t R aa (where t is 1 or 2), -R bb -S(O) t OR aa (where t is 1 or 2) and -R bb -S(O) t N(R aa )2 (wherein t is 1 or 2); and wherein each R bb are independently selected from a direct bond or a straight or branched alkylene, alkenylene or alkynylene chain, and each R ccIt is a straight or branched alkylene, alkenylene or alkynylene chain.
[0175] Double bonds to oxygen atoms, such as oxo groups, are represented herein as both "=O" and "(O)". Double bonds to nitrogen atoms are represented as both "=NR" and "(NR)". Double bonds to sulfur atoms are represented as both "=S" and "(S)".
[0176] The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0177] As used herein, the phrase "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, etc. and soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer solution; and (21) other non-toxic compatible substances used in pharmaceutical preparations.
[0178] The term "salt" or "pharmaceutically acceptable salt" refers to salts derived from various organic and inorganic counterions known in the art. Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Organic bases from which salts can be derived include, for example, primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine and ethanolamine. In some embodiments, pharmaceutically acceptable base addition salts are selected from ammonium, potassium, sodium, calcium and magnesium salts.
[0179] In certain embodiments, the term "cosmetically acceptable salt" means any salt that is cosmetically tolerated if properly used in cosmetic treatments, particularly if used or applied to humans and / or mammals. In certain embodiments, these salts include, but are not limited to, salts used to form base addition salts, which are inorganic, such as and in a non-limiting sense, lithium, sodium, potassium, calcium, magnesium or aluminum salts, etc., or organic, such as and in a non-limiting sense, ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, arginine, lysine, histidine or piperazine salts, etc.; or acid addition salts, which are organic, such as and in a non-limiting sense, acetates, citrates, lactates, malonates, maleates, tartrates, fumarates, benzoates, aspartates, glutamates, succinates, oleates, trifluoroacetates, oxalates, pamoates or gluconates, etc., or inorganic, such as and in a non-limiting sense, chlorides, sulfates, borates or carbonates, etc.
[0180] As used herein, a "cosmetically effective amount" refers to an amount of a compound sufficient to improve the appearance of a subject. It should be understood that a "cosmetically effective" amount can vary from subject to subject due to many factors, including, for example, the subject's age, weight, general condition, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician.
[0181] As used herein, the phrase "cosmetically acceptable excipient" or "cosmetically acceptable carrier" includes pharmaceutical cream bases, oil-in-water emulsions, water-in-oil emulsions, gels, etc. Those skilled in the art will appreciate that suitable carriers typically contain ingredients such as those commonly found in the cosmetic and cosmeceutical arts: oils, waxes or other standard fatty substances, or conventional gelling agents and / or thickening agents; emulsifiers; moisturizers; emollients; sunscreens; hydrophilic or lipophilic active agents; agents to combat free radicals; preservatives; alkalizing or acidifying agents; fragrances; surfactants; fillers; natural products or extracts of natural products, such as aloe vera or green tea extracts; vitamins; or coloring materials.
[0182] The term "in vivo" generally refers to events occurring within the body of a subject.
[0183] The term "in vitro" generally refers to an event that occurs outside a subject. For example, an in vitro assay includes any assay that is performed outside a subject. In vitro assays include cell-based assays, in which live or dead cells are used. In vitro assays also include cell-free assays, in which intact cells are not used.
[0184] "Optional" or "optionally" means that the subsequently described event or circumstances may or may not occur, and that the description includes instances where the event or circumstances occurs and instances where the event or circumstances does not occur. For example, "optionally substituted aryl" means that the aryl group may or may not be substituted, and that the description includes both substituted aryl groups and aryl groups that are not substituted.
[0185] "Pharmaceutically acceptable carriers, diluents or excipients" include, but are not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye, colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the United States Food and Drug Administration as acceptable for use in humans or livestock.
[0186] Compound
[0187] The present disclosure provides compounds, salts thereof, and compositions and preparations thereof for skin treatment. The compound or its salt may have a structural formula (I), (II), (III), (IV), (V), (VI) or (VII). The compound or its salt may be selected from those shown in Tables 1-8, or any subset thereof. The compounds and salts thereof disclosed herein may be used in the methods of the present disclosure.
[0188] Compounds of formula (I) and salts thereof
[0189] In certain aspects, disclosed herein are compounds having the structure of Formula (I):
[0190]
[0191] or a (e.g., pharmaceutically or cosmetically acceptable) salt thereof, wherein:
[0192] R 1a and R 1b independently selected from H, alkyl and haloalkyl;
[0193] R 3 is selected from cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl or aralkyl is optionally substituted with one or more substituents independently selected from halogen, alkyl, alkoxy and haloalkoxy;
[0194] R x are each independently selected from halogen, alkyl, haloalkyl, alkenyl, haloalkenyl,
[0195] -OH, alkoxy, haloalkoxy, -NH2, alkylamino, dialkylamino, and haloalkylamino;
[0196] p is 1, 2, or 3;
[0197] q is 0, 1, or 2; and
[0198] Q is selected from O, S and NR 2 , where R 2 is selected from the group consisting of H, alkyl, alkenyl, haloalkyl, haloalkenyl, nitro, -NH2, alkylamino, dialkylamino and haloalkylamino.
[0199] In some embodiments of the compound having structural formula (I) (or a salt thereof), Q is NR 2 In some embodiments, R 2 is selected from amino, (e.g., C1-C3)alkyl, and (e.g., C1-C3)alkenyl. In some embodiments, R 2 is C1 alkyl. In some embodiments, R 2 is a C2 alkyl group. 2 is -CH2CHCH2. In some embodiments, R 2 Yes-NH 2 .
[0200] In some embodiments, R 1a and R 1b are independently selected from H, (e.g., C 1-6 , such as C 1-4 ) alkyl and (e.g., C 1-6 , such as C 1-4) haloalkyl. In some embodiments, R 1a and R 1b It's H.
[0201] In some embodiments, R 3 is selected from (e.g., C4-C6)cycloalkyl, (e.g., 5- or 6-membered)heterocyclyl, aryl (e.g., phenyl), heteroaryl (e.g., pyridine), alkylaryl, and aralkyl (e.g., benzyl). 3 yes In some embodiments, R 3 yes In some embodiments, R 3 yes In some embodiments, R 3 yes In some embodiments, R 3 yes In some embodiments, R 3 yes
[0202] In some embodiments, q is 0.
[0203] In some embodiments, the compound having structural formula (I) is selected from those shown in Table 1, and salts thereof.
[0204] Table 1. Exemplary compounds of formula (I)
[0205]
[0206] Compounds of formula (II) and salts thereof
[0207] In certain aspects, disclosed herein are compounds represented by formula (II):
[0208]
[0209] or a (e.g., pharmaceutically or cosmetically acceptable) salt thereof, wherein:
[0210] R 1a and R 1b are each independently selected from H, alkyl, haloalkyl, alkenyl, haloalkenyl, aryl (e.g., phenyl), and aralkyl (e.g., benzyl);
[0211] R x are each independently selected from halogen, alkyl, haloalkyl, alkenyl, haloalkenyl,
[0212] -OH, alkoxy, haloalkoxy, nitro, -NH2, alkylamino, dialkylamino, and haloalkylamino;
[0213] p is 1, 2, or 3;
[0214] q is 0, 1, or 2;
[0215] R 2 is selected from the group consisting of H, alkyl, alkenyl, haloalkyl, haloalkenyl, nitro, -NH2, alkylamino, dialkylamino, alkyl-dialkylamino, and haloalkylamino; and
[0216] R 3 is selected from H, alkyl and haloalkyl.
[0217] In some embodiments, R 1a and R 1b are independently selected from H and (e.g., C 1-6 , such as C 1-4 In some embodiments, R 1a and R 1b Independently C 1-4 In some embodiments, R 1a and R 1b In some embodiments, R 1a and R 1b It's H.
[0218] In some embodiments, R x is C1 to C6 alkoxy. x It is -OCH3.
[0219] In some embodiments, q is 0 or 1. In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, p is 1.
[0220] In some embodiments, R 2 is (e.g., C1 to C6) alkyl, alkyl-dialkylamino, monoalkylamino (e.g., mono-(C1-C6) alkylamino) and dialkylamino (e.g., di(C1-C6) alkylamino). In some embodiments, alkyl-dialkylamino is, for example, (CH3CH2)2N(CH2)-. In some embodiments, alkylamino is, for example, -CH2NH-. In some embodiments, dialkylamino is, for example, (CH3CH2)2N-. In some embodiments, R 2 is a straight chain C2 alkyl group. 2 is a straight chain C3 alkyl group. 2 is a straight chain C4 alkyl group. 2 is a branched C3 alkyl group. 2is a branched C4 alkyl group. 2 is a branched C3 alkyl group. 2 is selected from methyl, ethyl, propyl, butyl, isopropyl, isobutyl and In some embodiments, R 3 It's H.
[0221] In some embodiments, the compound having structural formula (II) is selected from those shown in Table 2, and salts thereof.
[0222] Table 2. Exemplary compounds of formula (II)
[0223]
[0224]
[0225] Compounds of formula (III) and salts thereof
[0226] In certain aspects, disclosed herein are compounds represented by formula (III):
[0227]
[0228] or a (e.g., pharmaceutically or cosmetically acceptable) salt thereof, wherein:
[0229] L 1 , L 2 and L 3 are each independently selected from a bond or (e.g., C 1-6 , such as C 1-3 ) alkyl (eg
[0230] e.g., straight chain or branched chain);
[0231] A is N-amido, -NH-C(O)- or -C(O)-NH-;
[0232] Ring B is selected from (e.g., C4-C6)cycloalkyl, (e.g., 5- or 6-membered)heterocyclyl, aryl (e.g., phenyl), heteroaryl (e.g., imidazolyl), and aralkyl (e.g., benzyl);
[0233] R x and R y Each is independently selected from halogen, alkyl, haloalkyl, alkenyl, haloalkenyl, hydroxy, alkoxy, haloalkoxy, nitro, -NH2, alkylamino, dioxane
[0234] Alkylamino and haloalkylamino;
[0235] m is 0, 1, or 2; and
[0236] n is 0 or 1.
[0237] In some embodiments, L 1 , L 2 and L 3 Each is independently a bond. In some embodiments, L 1 , L 2 and L 3 Each independently is a straight chain C 1-6 In some embodiments, L 1 , L 2 and L 3 Each independently is a branched C 1-6 In some embodiments, L 1 , L 2 and L 3 Each independently is a straight chain C 1-3 In some embodiments, L 1 , L 2 and L 3 Each independently is a branched C 1-3 alkyl.
[0238] In some embodiments, A is N-amido. In some embodiments, A is -NH-C(O)-. In some embodiments, A is -C(O)-NH-.
[0239] In some embodiments, for compounds of formula (III) or salts thereof, ring B is selected from aryl (e.g., phenyl), heteroaryl (e.g., imidazolyl), and aralkyl (e.g., benzyl). In some embodiments, ring B is selected from aryl (e.g., phenyl) and heteroaryl (e.g., imidazolyl). In some embodiments, ring B is selected from phenyl and imidazolyl. In some embodiments, ring B is In some embodiments, Ring B is
[0240] In some embodiments, R x is C1-C3 alkoxy. x It is -OCH3.
[0241] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, n is 0.
[0242] In some embodiments, the compound having structural formula (III) is selected from those shown in Table 3, and salts thereof.
[0243] Table 3. Example compounds of formula (III)
[0244]
[0245] Compounds of formula (IV) and salts thereof
[0246] In certain aspects, disclosed herein are compounds (IV) represented by the formula:
[0247]
[0248] or a (e.g., pharmaceutically or cosmetically acceptable) salt thereof, wherein:
[0249] R 1 is selected from alkyl or heterocycloalkyl, wherein R 1 The alkyl or heterocycloalkyl of is optionally independently selected from heterocycloalkyl (e.g., )、-C(O)NR x1 R x2 , alkoxy, -
[0250] (C1-C3 alkylene)-C(O)OR y1 、-C(O)OR y2 AND-OR z substituted with one or more substituents; wherein:
[0251] R x1 , R x2 , R y1 , R y2 and R z are each independently selected from H, alkyl and haloalkyl; and
[0252] X is -O-, -S- or -NR B -; R A is H, alkyl or haloalkyl;
[0253] R 2 and R 3 Each independently selected from H, (e.g., C 1-6 , such as C 1-3 ) alkyl (e.g., linear or branched); or alternatively, R 2 and R 3 together with the atoms to which they are attached to form (e.g., C4-C6) cycloalkyl or aryl (e.g., phenyl), wherein the cycloalkyl or aryl is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl,
[0254] The dashed lines indicate the presence of single or double bonds.
[0255] In some embodiments, the compound of formula (IV) has the structural formula:
[0256] (For example, ).
[0257] In some embodiments, the compound of formula (IV) has the structural formula
[0258]
[0259] In some embodiments, the compound of formula (IV) has the structural formula:
[0260] (For example, ).
[0261] In some embodiments, the compound of formula (IV) has the structural formula:
[0262]
[0263] In some embodiments, X is -O-. In some embodiments, X is -NR B -, optionally, wherein R B It's H.
[0264] In some embodiments, R 1 Selected from -(CH2) a C(O)OH, -(CH2) a OCH3, -(CH2) a CH(OH)CH3, wherein: a is 0, 1, 2 or 3. In some embodiments, R 1 Selected from –(CH2) a C(O)OH, -(CH2) a OCH3, -(CH2) a CH(OH)CH3, wherein: a is 0, 1, 2 or 3. In some embodiments, R 1 Selected from -CH2C(O)OH, -(CH2)2OCH3, CH2CH(OH)CH3, In some embodiments, R x1 and R x2 Each is independently C1-C6 (e.g., C1-C3) alkyl. y1 is H. In some embodiments, R y2 is H. In some embodiments, R z It's H.
[0265] In some embodiments, R 1 is optionally independently selected from heterocycloalkyl (e.g., )、-C(O)NR x1 R x2, alkoxy, -(C1-C3 alkylene)-C(O)OR y1 、-C(O)OR y2 AND-OR z One or more substituents substituted with C 1-4 In some embodiments, R 1 is optionally substituted with one or more heterocycloalkyl groups (e.g. ) substituted C1 alkyl. In some embodiments, R 1 is optionally substituted by a heterocycloalkyl group (e.g. ) substituted C1 alkyl. In some embodiments, R 1 yes In some embodiments, the C1 alkyl group is optionally replaced by one or more -C(O)NR x1 R x2 In some embodiments, R 1 is a C1 alkyl group optionally substituted with one or more -C(O)NCH3CH3. 1 is optionally replaced by a In some embodiments, R 1 yes In some embodiments, R 1 is alkyl optionally substituted with one or more alkoxy groups. 1 Yes - (CH2) a OCH3, wherein a is 0, 1, 2 or 3. In some embodiments, R 1 is -(CH2)OCH3. In some embodiments, R 1 is -(CH2)2OCH3. In some embodiments, R 1 It is -(CH2)3OCH3. 1 is optionally followed by one or more -OR z In some embodiments, R 1 is one or more -OR z Substituted C3 alkyl, wherein R z is H. In some embodiments, R 1 is CH2CH(OH)CH3. In some embodiments, R 1 is optionally independently selected from heterocycloalkyl (e.g., )、-C(O)NR x1 R x2 , alkoxy, -(C1-C3 alkylene)-C(O)OR y1 、-C(O)OR y2 AND-OR zIn some embodiments, R 1 is optionally independently selected from -(C1-C3 alkylene)-C(O)OR y1 A heterocycloalkyl group substituted with one or more substituents, wherein R y1 is H. In some embodiments, the heterocycloalkyl is In some embodiments, R 1 yes In some embodiments, R 1 is optionally substituted with one or more -C(O)OR y2 Substituted C1 alkyl, wherein R y2 is H. In some embodiments, R 1 It is -CC(O)OH.
[0266] In some embodiments, R 2 and R 3 Each is independently selected from C1-C6 alkyl. 2 and R 3 Together with the atoms to which they are attached, they form a C4-C6 cycloalkyl group (e.g., cyclohexyl), which is optionally substituted with one or more substituents independently selected from halogen, alkyl, and haloalkyl. 2 and R 3 Together with the atoms to which they are attached, they form a cyclohexyl group, which is optionally substituted with one or more substituents independently selected from halogen, alkyl, and haloalkyl. 2 and R 3 Together with the atoms to which they are attached, they form an aryl group (e.g., phenyl), which is optionally substituted with one or more substituents independently selected from halogen, alkyl, and haloalkyl. 2 and R 3 Together with the atoms to which they are attached, to form a phenyl group, which is optionally substituted with one or more substituents independently selected from halogen, alkyl, and haloalkyl. A It's H.
[0267] In some embodiments, the compound having structural formula (IV) is selected from those shown in Table 4, and salts thereof.
[0268] Table 4. Exemplary compounds of formula (IV)
[0269]
[0270] Compounds of formula (V) and salts thereof
[0271] In certain aspects, disclosed herein are compounds represented by formula (V):
[0272]
[0273] or a (e.g., pharmaceutically or cosmetically acceptable) salt thereof, wherein:
[0274] Y 1 O, S or NR 1 , where R 1 is H, alkyl or haloalkyl;
[0275] R 2 is selected from the group consisting of H, alkyl, haloalkyl, alkenyl, haloalkenyl, aryl (e.g., phenyl), and aralkyl (e.g., benzyl); and
[0276] R 3 Selected from H, alkyl, haloalkyl, -(CH2) m1 -OR a1 、-(CH2) m2 -O-(CH2) m3 -OR a2 、-(CH2) m4 -NR b1 R b2 、(CH2) m5 -C(O)OR c ,in:
[0277] R a1 , R a2 , R b1 , R b2 and R c are each independently selected from H, alkyl and haloalkyl; and
[0278] m1, m2, m3, m4 and m5 are each independently selected from 1, 2, 3 and 4.
[0279] In some embodiments, for the compound of formula (V) or a salt thereof, Y 1 is O or S. In some embodiments, Y 1 is O. In some embodiments, R a1 , R a2 , R b1 , R b2 and R c Each is independently C1-C6 alkyl, such as C1-C3 alkyl. a1 is C1 alkyl. In some embodiments, R a1 is a C2 alkyl group. a1 is a C3 alkyl group. a2 is C1 alkyl. In some embodiments, Ra2 is a C2 alkyl group. a2 is a C3 alkyl group. b1 is C1 alkyl. In some embodiments, R b1 is a C2 alkyl group. b1 is a C3 alkyl group. b2 is C1 alkyl. In some embodiments, R b2 is a C2 alkyl group. b2 is a C3 alkyl group. c is C1 alkyl. In some embodiments, R c is a C2 alkyl group. c is a C3 alkyl group. 2 It's H.
[0280] In some embodiments, m1 is selected from 1, 2, 3, and 4. In some embodiments, m1 is 1. In some embodiments, m1 is 2. In some embodiments, m1 is 3. In some embodiments, m1 is 4. In some embodiments, m2 is selected from 1, 2, 3, and 4. In some embodiments, m2 is 1. In some embodiments, m2 is 2. In some embodiments, m2 is 3. In some embodiments, m2 is 4. In some embodiments, m3 is selected from 1, 2, 3, and 4. In some embodiments, m3 is 1. In some embodiments, m3 is 2. In some embodiments, m3 is 3. In some embodiments, m3 is 4. In some embodiments, m4 is selected from 1, 2, 3, and 4. In some embodiments, m4 is 1. In some embodiments, m4 is 2. In some embodiments, m4 is 3. In some embodiments, m4 is 4. In some embodiments, m5 is selected from 1, 2, 3, and 4. In some embodiments, m5 is 1. In some embodiments, m5 is 2. In some embodiments, m5 is 3. In some embodiments, m5 is 4.
[0281] In some embodiments, the compound having structural formula (V) is selected from those shown in Table 5, and salts thereof.
[0282] Table 5. Exemplary compounds of formula (V)
[0283]
[0284]
[0285] Compounds of formula (VI) and salts thereof
[0286] In certain aspects, disclosed herein are compounds (VI) represented by the formula:
[0287]
[0288] or a (e.g., pharmaceutically or cosmetically acceptable) salt thereof, wherein:
[0289] R a (when present) are each independently selected from alkyl, haloalkyl, alkenyl, haloalkenyl and alkoxy;
[0290] R 1 and R 2 One of is H or alkyl;
[0291] R 1 and R 2 The other one is selected from H, alkyl, alkoxy, -(C1-C6 alkylene)-C(O)NR x1 -(C1-C6 alkylene)-aryl and -(C1-C6 alkylene)-C(O)NR x2 -(C1-C6 alkyl), where R x1 and R x2 are each independently H, alkyl or haloalkyl; and
[0292] p is 0, 1 or 2.
[0293] In certain embodiments, for the compound of formula (VI) or a salt thereof, R x1 is H. In some embodiments, R x2 It's H.
[0294] In some embodiments, R 1 and R 2 One of is H. In some embodiments, R 1 and R 2 The other of is selected from C1-C6 (e.g., C1-C3) alkyl, In some embodiments, R 1 and R 2 The other one of which is selected from isopropyl, In some embodiments, R 1 and R 2 In some embodiments, R 1 and R 2 The other one is In some embodiments, R 1 and R 2 The other one is
[0295] In some embodiments, p is 0. In some embodiments, p is 1.
[0296] In some embodiments, R a is C1-C6 (eg, C1-C3) alkyl or C1-C6 (eg, C1-C3) alkoxy. a is -CH3. In some embodiments, R a It is -OCH3.
[0297] In some embodiments, the compound having structural formula (VI) is selected from those shown in Table 6, and salts thereof.
[0298] Table 6. Exemplary compounds of formula (VI)
[0299]
[0300] Compounds of formula (VII) and salts thereof
[0301] In certain aspects, disclosed herein are compounds represented by formula (VII):
[0302]
[0303] or a (e.g., pharmaceutically or cosmetically acceptable) salt thereof, wherein:
[0304] A is selected from O, NH, S;
[0305] R 1 Selected from hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 2-10 Alkynyl, C 3-12 Carbocyclic and 3- to 12-membered heterocyclic rings;
[0306] R 2 is selected from a 6- to 10-membered heterocyclic ring, wherein the 6- to 10-membered heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, -OR 11 、-SR 11 , -NO2, =O, =NH, -CN, -C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2.-NR 11 S(O)2R11 、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )C(O)OR 11 、-S(O)2(R 11 )、-S(O)2N(R 11 2. C 1-10 Alkyl, C3-C 12 Carbocyclic and 5- to 12-membered heterocyclic rings;
[0307] n is selected from 1, 2, 3, 4, 5 and 6;
[0308] Each R 11 is independently selected at each occurrence from hydrogen; C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-12 carbocyclic rings, each of which is optionally substituted with one or more substituents selected from 3- to 6-membered heterocyclic rings.
[0309] In some embodiments, A is oxygen. In some embodiments, R 1 It is C 1-6 In some embodiments, C 1-6 Alkyl is C1 alkyl. In some embodiments, R 1 It is -CH3.
[0310] In some embodiments, n is selected from 1 and 3. In some embodiments, n is selected from 1. In some embodiments, n is selected from 3.
[0311] In some embodiments, R 2 The 6- to 10-membered heterocyclic ring is selected from pyran, pyridine, piperidine, imidazole, thiazole, dioxane, morpholine, pyrimidine, benzimidazole, piperazine, thiadiazine, oxepane, thiepine, azoctatetraene, indole, isoindole, indolizine, quinoline, isoquinoline, purine, carbazole and dibenzofuran. In some embodiments, R 2 The 6- to 10-membered heterocyclic ring is benzimidazole, In some embodiments, the 6- to 10-membered heterocyclic ring R 2 Piperazine, In some embodiments, piperazine is optionally independently selected from ═O and —C(O)R 11 is substituted with one or more substituents.
[0312] In some embodiments, R11 is C substituted by one or more substituents selected from 3- to 6-membered heterocyclic rings 1-6 In some embodiments, R 11 is C1 alkyl or C2 alkyl. In some embodiments, the 3- to 6-membered heterocyclic ring is
[0313] In some embodiments, each R 2 Selected from:
[0314]
[0315] In some embodiments, the compound having structural formula (VII) is selected from those shown in Table 7, and salts thereof.
[0316] Table 7. Exemplary compounds of formula (VII)
[0317]
[0318] Other compounds and their salts
[0319] In some embodiments, the compounds disclosed herein are selected from those shown in Table 8, and salts thereof.
[0320] Table 8. Examples of other compounds
[0321]
[0322]
[0323]
[0324]
[0325]
[0326] In some embodiments, the compounds disclosed herein are selected from those shown in any one or combination of Tables 1 to 8 (or any subset thereof), and salts thereof.
[0327] The compounds of the present invention also include crystalline and amorphous forms of those compounds, pharmaceutically acceptable salts and active metabolites of these compounds having the same type of activity, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrates), conformational polymorphs and amorphous forms of the compounds, and mixtures thereof.
[0328] Included in the present disclosure are salts of the compounds described herein, particularly pharmaceutically acceptable salts. Compounds of the present disclosure having sufficient acidity, sufficient basicity, or both functional groups can react with any of a number of inorganic bases and inorganic and organic acids to form salts. Alternatively, inherently charged compounds, such as those having quaternary nitrogen, can form salts with appropriate counterions, for example, halide salts such as bromide, chloride, or fluoride salts, particularly bromide salts.
[0329] Compounds described herein may exist as diastereomers, enantiomers or other stereoisomeric forms in some cases. Compounds proposed herein include all diastereomers, enantiomers and epimeric forms and suitable mixtures thereof. Separation of stereoisomers can be carried out by chromatography or by forming diastereomers and separating by recrystallization or chromatography or any combination thereof (Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley and Sons, Inc., 1981, incorporated herein by reference for the present disclosure). Stereoisomers can also be obtained by stereoselective synthesis.
[0330] The methods and compositions described herein include the use of amorphous forms as well as crystalline forms (also referred to as polymorphs). The compounds described herein may be in the form of pharmaceutically acceptable salts. Likewise, in some embodiments, active metabolites of these compounds having the same type of activity are included within the scope of the present disclosure. In addition, the compounds described herein may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the compounds presented herein are also considered to be disclosed herein.
[0331] Synthetic chemistry transformations and methods for synthesizing the compounds described herein are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations (1989); T. W. Greene and PGM Wuts, Protective Groups in Organic Synthesis, Second Edition (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis (1995).
[0332] Composition
[0333] The present disclosure provides compositions of the compounds disclosed herein and salts thereof.
[0334] In some embodiments, the composition is for preventing or treating a skin condition, disorder or disease, comprising a compound having a structure of Formula (I), (II), (III), (IV), (V), (VI), (VII) or Table 8. The composition is for treating a skin condition, disorder or disease, comprising a compound having a structure of Formula (I), (II), (III), (IV), (V), (VI), (VII) or Table 8. In some embodiments, the weight % of the compound in the composition accounts for from about 0.05% to about 10.0% by weight relative to the total weight of the composition. In some embodiments, the weight % of the compound in the composition accounts for from about 0.01% to about 5%. In some embodiments, the weight % of the compound in the composition accounts for from about 0.01% to about 2.0%. In some embodiments, the weight % of the compound in the composition accounts for from about 0.01% to about 10% by weight relative to the total weight of the composition. In some embodiments, the weight % of the compound in the composition relative to the total weight of the composition is at least about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% by weight. In some embodiments, the weight % of the compound in the composition comprises up to about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% by weight relative to the total weight of the composition. In some embodiments, the weight % of the compound in the composition, relative to the total weight of the composition, comprises from about 0.01 to 10, 0.02 to 9, 0.03 to 8, 0.04 to 7, 0.05 to 6, 0.06 to 5, 0.07 to 4, 0.08 to 3, 0.09 to 2, 0.1 to 1, 0.2 to 0.9, 0.3 to 0.8, 0.4 to 0.7, or 0.5 to 0.6% by weight.
[0335] The compositions disclosed herein may also include at least one additive selected from, but not limited to, water, preservatives, antioxidants, sunscreens, surfactants, emulsifiers, opacifiers, volatiles, propellants, liquid vehicles, carriers, salts, pH adjusters, neutralizers, buffers, natural extracts, humectants, fragrances, spices, oils, emollients, lubricants, butters, penetrants, thickeners, viscosity modifiers, polymers, resins, film formers, adsorbents, oils, moisturizers, whitening agents, anti-wrinkle agents and acne relievers, allergy relievers, sunscreens, hair restoration agents, vitamins and derivatives, amino acids or polypeptides, anti-inflammatory agents, female hormones, exfoliants, fungicides, placenta, allantoin, yeast extracts, collagen, elastin, DHA, EPA, ceramides, and combinations thereof, so as to achieve a near commercially available product form. The compositions disclosed herein for preventing or treating skin conditions, disorders, or diseases may be formulated in any suitable physical form. For example, in some embodiments, suitable physical forms include, but are not limited to, toners, lotions, creams, gels, conditioners, soaps, serums, sprays, low to medium viscosity liquids, lotions, emulsions, mousses, oils, etc. In some embodiments, the composition is formulated to be applied by atomization, wiping, rubbing, wetting, dripping, or spraying.
[0336] In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the pharmaceutical composition comprises a compound having a structure of formula (I), (II), (III), (IV), (V), (VI) or (VII) or a salt thereof. In some embodiments, the pharmaceutical composition comprises a compound having a structure in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7 or Table 8 or a salt thereof. The pharmaceutical composition may also include at least one additive selected from a pharmaceutically acceptable carrier, excipient, adjuvant, diluent and a combination thereof to achieve a form close to a commercially available product.
[0337] In some embodiments, the composition is a cosmetic composition. In some embodiments, the cosmetic composition comprises a compound or salt thereof having a structure of formula (I), (II), (III), (IV), (V), (VI) or (VII). In some embodiments, the cosmetic composition comprises a compound or salt thereof having a structure in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7 or Table 8. The cosmetic composition may also include at least one additive selected from cosmetically acceptable carriers, excipients, adjuvants, diluents and combinations thereof, so as to achieve a product form close to commercial availability. The composition may be formulated as a liquid solution. The cosmetic composition disclosed herein may be formulated into any suitable physical form. For example, in some embodiments, suitable physical forms include but are not limited to toners, lotions, creams, gels, conditioners, soaps, essences, sprays, low to medium viscosity liquids, lotions, emulsions, mousses, oils, etc. In some embodiments, the composition may be used as a spray. In some embodiments, the composition may be used as a mist.
[0338] In some embodiments, non-limiting examples of skin include facial skin, elbow skin, neck skin, hand skin, skin around joints, or a combination thereof. In some embodiments, facial skin includes skin of the forehead, temples, zygomatic region, nasolabial folds, marionette lines, chin, mandible, midface, preauricular region, periorbital depressions, cheeks, jawline, lips, or any combination thereof.
[0339] In some embodiments, the composition disclosed herein prevents or reduces wrinkles or fine lines. In some embodiments, the composition disclosed herein increases skin firmness. In some embodiments, the composition disclosed herein fades age spots. In some embodiments, the composition disclosed herein softens rough skin patches. In some embodiments, the composition disclosed herein moisturizes / hydrates the skin. In some embodiments, the composition disclosed herein protects the skin from UV damage. In some embodiments, the composition disclosed herein increases skin collagen production or collagen deposition cell proliferation. In some embodiments, the composition disclosed herein increases fibroblast proliferation. In some embodiments, the composition disclosed herein heals wounds.
[0340] Non-limiting examples of compositions are shown in Tables 9 to 13. Compositions can include any aspect or combination of aspects from any of these tables. A, B, C, D, and E in Tables 9 to 13 represent example ranges of percentage weights of each ingredient. For example, A refers to a value less than about 0.5%, B refers to a value equal to or greater than about 0.5% and less than about 2%, C represents a value equal to or greater than about 2% and less than about 10%, and D refers to a value equal to or greater than about 10%. Based on these examples, compositions can include any aspect thereof in the amounts shown in Tables 9 to 13.
[0341] Table 9. Composition examples
[0342]
[0343] Table 10. Composition examples
[0344]
[0345]
[0346] Table 11. Composition examples
[0347] Element %weight water D Xanthan gum A Propylene glycol C glycerin C Caprylic / capric triglyceride C Isostearyl Isostearate C Lauryl Lactate C Dicaprylyl carbonate C Cetearyl Alcohol (and) Cetearyl Glucoside C Arachidyl alcohol (and) behenyl alcohol (and) arachidyl glucoside B Glyceryl Stearate C Isosorbide dimethyl ether C Ethoxydiglycol C Polyglyceryl-4 Caprate B Polyacrylate Crosspolymer-6 B Compounds disclosed herein B Phenoxyethanol B Chlorphenesin A Disodium EDTA A Vinyl dimethyl / methyl silsesquioxane copolymer B Fragrance A
[0348] Table 12. Composition examples
[0349]
[0350] Table 13. Composition examples
[0351] Element %weight water D Propylene glycol C glycerin C Caprylic / capric triglyceride C Isostearyl Isostearate C Lauryl Lactate C Dicaprylyl carbonate C Polyacrylamide & C13-14 Isoparaffin & Laureth-7 C Isosorbide dimethyl ether C Ethoxydiglycol C Polyglyceryl-4 Caprate B Compounds disclosed herein B Phenoxyethanol B Ethylhexylglycerin A Boron Nitride B Fragrance A
[0352] In Tables 9-13, the "compounds disclosed herein" may include compounds having a structure of Formula (I), (II), (III), (IV), (V), (VI), (VII) or Table 8, or a salt thereof. In Tables 9-13, the "compounds disclosed herein" may include compounds having a structure in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7 or Table 8, or a salt thereof.
[0353] In some embodiments, disclosed herein is a formulation comprising an aspect of any one of Tables 9-13 or a combination of aspects. Any one of Tables 9-13 or a combination of aspects may each comprise 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09% or 0.1% or a composition of a range defined by any two of the above percentages. The percentage may be weight / weight or weight / volume. An aspect or combination of aspects of any one of Tables 9-13 can each comprise about 0.001%, about 0.002%, about 0.003%, about 0.004%, about 0.005%, about 0.006%, about 0.007%, about 0.008%, about 0.009%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09% or about 0.1% or a composition of a range defined by any two of the above percentages. An aspect or combination of aspects of any one of Tables 9-13 can each contain at least 0.001%, at least 0.002%, at least 0.003%, at least 0.004%, at least 0.005%, at least 0.006%, at least 0.007%, at least 0.008%, at least 0.009%, at least 0.01%, at least 0.02%, at least 0.03%, at least 0.04%, at least 0.05%, at least 0.06%, at least 0.07%, at least 0.08%, at least 0.09%, or at least 0.1% of the composition. An aspect or combination of aspects of any one of Tables 9-13 may each contain no more than 0.001%, no more than 0.002%, no more than 0.003%, no more than 0.004%, no more than 0.005%, no more than 0.006%, no more than 0.007%, no more than 0.008%, no more than 0.009%, no more than 0.01%, no more than 0.02%, no more than 0.03%, no more than 0.04%, no more than 0.05%, no more than 0.06%, no more than 0.07%, no more than 0.08%, no more than 0.09% or no more than 0.1% of the composition.Any aspect or combination of aspects of Tables 9-13 can each comprise 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% or a composition of a range defined by any two of the above percentages. The percentages can be weight / weight or weight / volume. An aspect or combination of aspects of any one of Tables 9-13 can each comprise about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2.5%, about 5%, about 7.5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% or about 100% or a composition of a range defined by any two of the above percentages. An aspect or combination of aspects of any one of Tables 9-13 can each comprise at least 0.1%, at least 0.2%, at least 0.3%, at least 0.4%, at least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least 0.9%, at least 1%, at least 2.5%, at least 5%, at least 7.5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% of the composition. An aspect or combination of aspects of any one of Tables 9-13 can each contain no more than 0.1%, no more than 0.2%, no more than 0.3%, no more than 0.4%, no more than 0.5%, no more than 0.6%, no more than 0.7%, no more than 0.8%, no more than 0.9%, no more than 1%, no more than 2.5%, no more than 5%, no more than 7.5%, no more than 10%, no more than 15%, no more than 20%, no more than 25%, no more than 30%, no more than 35%, no more than 40%, no more than 45%, no more than 50%, no more than 55%, no more than 60%, no more than 65%, no more than 70%, no more than 75%, no more than 80%, no more than 85%, no more than 90% or no more than 95% of the composition.
[0354] method
[0355] Also provided herein are methods of skin treatment using the compounds or salts disclosed herein.
[0356] In certain aspects, disclosed herein is a method for preventing or treating a skin condition, disorder or disease (regardless of whether a diagnosis of the skin condition, disorder or disease has been made). In some embodiments, the method is used to treat a skin condition, disorder or disease. In some embodiments, the method includes administering a composition comprising a compound or a salt thereof as described herein or a composition as described herein to a subject in need thereof. The compound or its salt therein may have the structural formula of (I), (II), (III), (IV), (V), (VI), (VII) or Table 8. The compound or its salt therein may be selected from any one of Tables 1-8 or those shown in any subset thereof, or any combination thereof. In some embodiments, the method includes using, applying or applying a compound or its salt having a structure of formula (I), (II), (III), (IV), (V), (VI) or (VII). In some embodiments, the method includes using, applying or applying a compound or its salt having a structure in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7 or Table 8.
[0357] A diagnosis of a skin condition, disorder, or disease may or may not have been made. In some embodiments of any of the methods described herein, the subject may have been diagnosed with a skin condition, disorder, or disease. In some embodiments of any of the methods described herein, the subject may not have been diagnosed with a skin condition, disorder, or disease.
[0358] In some embodiments, the method comprises applying the composition to a skin area of the subject. In some embodiments, the skin area is facial skin, elbow skin, neck skin, hand skin, or periarticular skin. In some embodiments, facial skin includes the skin of the forehead, temples, zygomatic region, nasolabial folds, marionette lines, chin, mandible, midface, preauricular region, periorbital depression, cheeks, jawline, lips, or any combination thereof.
[0359] In some embodiments, the method prevents or reduces wrinkles or fine lines. In some embodiments, the method increases skin firmness. In some embodiments, the method fades age spots. In some embodiments, the method softens rough skin patches. In some embodiments, the method moisturizes / hydrates the skin. In some embodiments, the method protects the skin from UV damage. In some embodiments, the method increases skin collagen production or collagen depositing cell proliferation. In some embodiments, the method increases fibroblast proliferation. In some embodiments, the method heals wounds.
[0360] In some embodiments, the method comprises applying a composition to the skin area of the subject. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the pharmaceutical composition further comprises at least one additive selected from a pharmaceutically acceptable carrier, excipient, adjuvant, diluent, and combinations thereof, so as to achieve a close to commercially available product form.
[0361] In some embodiments, the pharmaceutical composition is administered one to three times per day. In some embodiments, the pharmaceutical composition is administered once per day. In some embodiments, the pharmaceutical composition is administered twice per day. In some embodiments, the pharmaceutical composition is administered three times per day. In some embodiments, the pharmaceutical composition is administered once every other day. In some embodiments, the pharmaceutical composition is administered at least for 2 consecutive days. In some embodiments, the pharmaceutical composition is administered at least for 3 consecutive days. In some embodiments, the pharmaceutical composition is administered at least for 4 consecutive days. In some embodiments, the pharmaceutical composition is administered at least for 5 consecutive days. In some embodiments, the pharmaceutical composition is administered at least for 7 consecutive days.
[0362] In some embodiments, the pharmaceutical composition is administered for at least about 2 days, 3 days, 5 days, 7 days, 10 days, 15 days, 20 days, 30 days, 50 days, 60 days, 80 days, 90 days, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, or 3 years. In some embodiments, the pharmaceutical composition is administered for up to about 2 days, 3 days, 5 days, 7 days, 10 days, 15 days, 20 days, 30 days, 50 days, 60 days, 80 days, 90 days, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, or 3 years. In some embodiments, the pharmaceutical composition is administered for about 2 days to 3 years, 3 days to 2 years, 5 days to 1 year, 7 days to 11 months, 10 days to 10 months, 15 days to 9 months, 20 days to 8 months, 30 days to 7 months, 50 days to 6 months, 60 days to 5 months, 80 days to 4 months, or 90 days to 3 years.
[0363] In some embodiments, the composition is a cosmetic composition. In some embodiments, the cosmetic composition further comprises at least one additive selected from cosmetically acceptable carriers, excipients, adjuvants, diluents and combinations thereof, so as to achieve a close commercially available product form. The composition can be formulated as a liquid solution. The cosmetic composition disclosed herein can be formulated into any suitable physical form. For example, in some embodiments, suitable physical forms include but are not limited to toners, emulsions, creams, gels, conditioners, soaps, essences, sprays, low to medium viscosity liquids, lotions, emulsions, mousses, oils, etc.
[0364] Numbered implementation plan
[0365] Some aspects include any of the following numbered embodiments:
[0366] 1. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of formula (V) or a salt thereof:
[0367]
[0368] in:
[0369] Y 1 O, S or NR 1 , where R 1 is H, alkyl or haloalkyl;
[0370] R 2 is selected from the group consisting of H, alkyl, haloalkyl, alkenyl, haloalkenyl, aryl, and aralkyl; and
[0371] R 3 Selected from H, alkyl, haloalkyl, -(CH2) m1 -OR a1 、-(CH2) m2 -O-(CH2) m3 -
[0372] OR a2 、-(CH2) m4 -NR b1 R b2 、(CH2) m5 -C(O)OR c ,in:
[0373] R a1 , R a2 , R b1 , R b2 and R c are each independently selected from H, alkyl and haloalkyl; and
[0374] m1, m2, m3, m4 and m5 are each independently selected from 1, 2, 3 and 4.
[0375] 2. The method according to embodiment 1, wherein Y 1 It is O or S.
[0376] 3. The method according to embodiment 1 or 2, wherein Y 1 It's O.
[0377] 4. The method according to any one of embodiments 1 to 3, wherein R a1 , R a2 , R b1, R b2 and R c Each is independently a C1-C6 alkyl group.
[0378] 5. The method according to any one of embodiments 1 to 4, wherein R a1 , R a2 , R b1 , R b2 and R c Each is independently a C1-C3 alkyl group.
[0379] 6. The method according to embodiment 5, wherein R a1 , R a2 , R b1 , R b2 and R c Each is independently a C1 alkyl group or a C2 alkyl group.
[0380] 7. The method according to any one of embodiments 1 to 6, wherein m1, m2, m3 and m4 are each independently 2 or 3.
[0381] 8. The method according to any one of embodiments 1 to 7, wherein m5 is 1.
[0382] 9. The method according to any one of embodiments 1 to 8, wherein R 2 It's H.
[0383] 10. The method according to embodiment 1, wherein the compound of formula (V) or a salt thereof is selected from: and salts of any of them.
[0384] 11. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (IV) or a salt thereof:
[0385]
[0386] in:
[0387] R 1 is selected from alkyl or heterocycloalkyl, wherein R 1 The alkyl or heterocycloalkyl of x1 R x2 , alkoxy, -(C1-C3 alkylene)-
[0388] C(O)OR y1 、-C(O)OR y2 AND-OR z substituted with one or more substituents; wherein:
[0389] R x1 , R x2 , R y1 , R y2 and R z are each independently selected from H, alkyl and haloalkyl;
[0390] R A is H or alkyl;
[0391] X is -O-, -S- or -NR B -; R B is H, alkyl or haloalkyl;
[0392] R 2 and R 3 are each independently selected from H, linear C1-C6 alkyl, branched C1-C6 alkyl; or alternatively, R 2 and R 3 together with the atoms to which they are attached to form a C4-C6 cycloalkyl or aryl group, wherein the cycloalkyl or aryl group is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl; and
[0393] The dashed lines indicate the presence of single or double bonds.
[0394] 12. The method according to embodiment 11, wherein the compound of formula (IV) has the structural formula:
[0395] 13. The method according to embodiment 12, wherein the compound of formula (IV) has the structural formula:
[0396] 14. The method according to embodiment 11, wherein the compound of formula (IV) has the structural formula:
[0397] 15. The method according to embodiment 14, wherein the compound of formula (IV) has the structural formula:
[0398] 16. The method according to any one of embodiments 11-15, wherein R 2 and R 3 Each is independently selected from C1-C6 alkyl.
[0399] 17. The method according to any one of embodiments 11-15, wherein R 2 and R 3 Together with the atoms to which they are attached to form a C4-C6 cycloalkyl group optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl.
[0400] 18. The method according to embodiment 17, wherein R 2 and R 3 Together with the atoms to which they are attached to form a cyclohexyl group, the cyclohexyl group is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl.
[0401] 19. The method according to any one of embodiments 11-15, wherein R 2 and R 3 Together with the atoms to which they are attached, they form C 5-8 Aryl, the C 5-8 The aryl group is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl.
[0402] 20. The method according to embodiment 19, wherein R 2 and R 3 Together with the atoms to which they are attached to form a phenyl group, the phenyl group is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl.
[0403] 21. The method according to any one of embodiments 11-20, wherein R A It's H.
[0404] 22. The method of any one of embodiments 11-21, wherein X is -O-.
[0405] 23. The method according to any one of embodiments 11-22, wherein X is -NR B -, optionally, wherein R B It's H.
[0406] 24. The method according to any one of embodiments 11-23, wherein R 1 Selected from: -(CH2) a C(O)OH, -(CH2) a OCH3, -(CH2) a CH(OH)CH3, Where: a is 0, 1, 2 or 3.
[0407] 25. The method according to any one of embodiments 11-24, wherein R 1 Selected from: -CH2C(O)OH, -(CH2)2OCH3, -CH2CH(OH)CH3,
[0408] 26. The method according to any one of embodiments 11-25, wherein R x1 and R x2 Each is independently a C1-C6 alkyl group.
[0409] 27. The method according to any one of embodiments 11-26, wherein R x1 and R x2 Each is independently a C1-C3 alkyl group.
[0410] 28. The method according to any one of embodiments 11-27, wherein R y1 It's H.
[0411] 29. The method according to any one of embodiments 11-28, wherein R y2 It's H.
[0412] 30. The method according to any one of embodiments 11-29, wherein R z It's H.
[0413] 31. The method according to embodiment 11, wherein the compound of formula (IV) or a salt thereof is selected from: and salts of any of them.
[0414] 32. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (VII) or a salt thereof:
[0415]
[0416] in:
[0417] A is selected from O, NH, S;
[0418] R 1 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 2-10 Alkynyl, C 3-12 Carbocyclic and 3- to 12-membered heterocyclic rings;
[0419] R 2 is selected from a 6- to 10-membered heterocyclic ring, wherein the 6- to 10-membered heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, -OR 11 、-SR 11, -NO2, =O, =NH, -CN, -C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2.-NR 11 S(O)2R 11 、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )C(O)OR 11 、-S(O)2(R 11 )、-S(O)2N(R 11 2. C 1-10 Alkyl, C3-C 12 Carbocyclic and 5- to 12-membered heterocyclic rings;
[0420] n is selected from 1, 2, 3, 4, 5 and 6;
[0421] Each R 11 is independently selected at each occurrence from hydrogen; C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-12 carbocyclic rings, each of which is optionally substituted with one or more substituents selected from 3- to 6-membered heterocyclic rings.
[0422] 33. A method according to embodiment 32, wherein A is O.
[0423] 34. The method according to embodiment 32 or 33, wherein R 1 It is C 1-6 alkyl.
[0424] 35. The method according to embodiment 34, wherein R 1 It is a C1 alkyl group.
[0425] 36. The method of any one of embodiments 32 to 35, wherein n is selected from 1 and 3.
[0426] 37. A method according to embodiment 36, wherein n is 1.
[0427] 38. A method according to embodiment 37, wherein n is 3.
[0428] 39. The method according to any one of embodiments 32 to 38, wherein R 2The 6- to 10-membered heterocyclic ring is selected from pyran, pyridine, piperidine, imidazole, thiazole, dioxane, morpholine, pyrimidine, benzimidazole, piperazine, thiadiazine, oxepane, thiene, azoctatetraene, indole, isoindole, indolizine, quinoline, isoquinoline, purine, carbazole and dibenzofuran.
[0429] 40. The method according to embodiment 39, wherein R 2 Selected from benzimidazole and piperazine.
[0430] 41. The method according to embodiment 40, wherein R 2 yes
[0431] 42. The method according to embodiment 40, wherein R 2 It's piperazine.
[0432] 43. The method according to embodiment 42, wherein piperazine is optionally independently selected from ═O and —C(O)R 11 is substituted with one or more substituents.
[0433] 44. The method according to any one of embodiments 32-43, wherein R 11 is C substituted by one or more substituents selected from 3- to 6-membered heterocyclic rings 1-6 alkyl.
[0434] 45. The method according to embodiment 44, wherein C 1-6 The alkyl group is a C1 alkyl group or a C2 alkyl group.
[0435] 46. The method according to embodiment 44 or 45, wherein the 3- to 6-membered heterocycle is
[0436] 47. The method according to any one of embodiments 32 to 46, wherein each R 2 Selected from:
[0437] 48. The method according to embodiment 32, wherein the compound of formula (VII) or a salt thereof is selected from:
[0438]
[0439] and salts of any of them.
[0440] 49. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (III) or a salt thereof:
[0441]
[0442] in:
[0443] L 1 , L 2 and L 3 Each independently selected from a bond, a straight chain C 1-6 Alkyl or branched C 1-6 alkyl;
[0444] A is N-amido, -NH-C(O)- or -C(O)-NH-;
[0445] Ring B is selected from C 4-6 Cycloalkyl, 5- or 6-membered heterocyclic group, C 5-8 Aryl, heteroaryl and aralkyl groups;
[0446] R x and R y Each is independently selected from halogen, alkyl, haloalkyl, alkenyl, haloalkenyl, hydroxy, alkoxy, haloalkoxy, nitro, -NH2, alkylamino, dialkylamino and haloalkylamino;
[0447] m is 0, 1, or 2; and
[0448] n is 0 or 1.
[0449] 50. The method according to embodiment 49, wherein ring B is selected from C 5-8 Aryl, heteroaryl and aralkyl.
[0450] 51. The method according to embodiment 49 or 50, wherein ring B is selected from C 5-8 Aryl and heteroaryl groups.
[0451] 52. The method according to embodiment 51, wherein C 5-8 Aryl is phenyl and heteroaryl is imidazolyl.
[0452] 53. The method according to any one of embodiments 49 to 52, wherein R x It is a C1-C3 alkoxy group.
[0453] 54. The method according to embodiment 53, wherein R x It is -OCH3.
[0454] 55. The method according to any one of embodiments 49 to 54, wherein Ring B is
[0455] 56. The method according to any one of embodiments 49 or 55, wherein ring B is
[0456] 57. The method of any one of embodiments 49 to 56, wherein m is 0 or 1.
[0457] 58. The method of any one of embodiments 49 to 57, wherein n is 0.
[0458] 59. The method according to embodiment 49, wherein the compound of formula (III) or a salt thereof is selected from:
[0459] and salts of any of them.
[0460] 60. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (II) or a salt thereof:
[0461]
[0462] in:
[0463] R 1a and R 1b are independently selected from H, alkyl, haloalkyl, alkenyl, haloalkenyl, C 5-8 Aryl and aralkyl groups;
[0464] R x are each independently selected from halogen, alkyl, haloalkyl, alkenyl, haloalkenyl,
[0465] -OH, alkoxy, haloalkoxy, nitro, -NH2, alkylamino, dialkylamino, and haloalkylamino;
[0466] p is 1, 2, or 3;
[0467] q is 0, 1, or 2;
[0468] R 2 is selected from the group consisting of H, alkyl, alkenyl, haloalkyl, haloalkenyl, nitro, -NH2, alkylamino, dialkylamino, alkyl-dialkylamino, and haloalkylamino; and
[0469] R 3 is selected from H, alkyl and haloalkyl.
[0470] 61. The method according to embodiment 60, wherein R 1a and R 1b Independently selected from H and C 1-6 alkyl.
[0471] 62. The method according to embodiment 60 or 61, wherein R 1a and R1b It's H.
[0472] 63. The method according to any one of embodiments 60 to 62, wherein R x It is a C1 to C6 alkoxy group.
[0473] 64. The method according to embodiment 62, wherein R x It is -OCH3.
[0474] 65. The method of any one of embodiments 60 to 64, wherein q is 0 or 1.
[0475] 66. The method of any one of embodiments 60 to 65, wherein p is 1.
[0476] 67. The method according to any one of embodiments 60 to 66, wherein R 2 It is C1-6 alkyl, alkyl-di(C1-C6)alkylamino, mono-(C1-C6)alkylamino and di(C1-C6)alkylamino.
[0477] 68. The method according to any one of embodiments 60 to 67, wherein R 2 is selected from methyl, ethyl, propyl, butyl, isopropyl, isobutyl and
[0478] 69. The method according to any one of embodiments 60 to 68, wherein R 3 It's H.
[0479] 70. The method according to embodiment 60, wherein the compound of formula (II) or a salt thereof is selected from: and salts of any of them.
[0480] 71. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (I) or a salt thereof:
[0481]
[0482] in:
[0483] R 1a and R 1b independently selected from H, alkyl and haloalkyl;
[0484] R 3 is selected from cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl or aralkyl is optionally substituted with one or more substituents independently selected from halogen, alkyl, alkoxy and haloalkoxy;
[0485] R x are each independently selected from halogen, alkyl, haloalkyl, alkenyl, haloalkenyl,
[0486] -OH, alkoxy, haloalkoxy, -NH2, alkylamino, dialkylamino, and haloalkylamino;
[0487] p is 1, 2, or 3;
[0488] q is 0, 1, or 2; and
[0489] Q is selected from O, S and NR 2 , where R 2 is selected from the group consisting of H, alkyl, alkenyl, haloalkyl, haloalkenyl, nitro, -NH2, alkylamino, dialkylamino and haloalkylamino.
[0490] 72. The method according to embodiment 71, wherein Q is NR 2 .
[0491] 73. The method according to embodiment 71 or 72, wherein R 2 Selected from amino, C1-3 alkyl and C 1-3 Alkenyl.
[0492] 74. The method according to any one of embodiments 71 to 73, wherein R 1a and R 1b Independently selected from H, C 1-6 Alkyl and C 1-6 Halogenated alkyl.
[0493] 75. The method according to any one of embodiments 71 to 74, wherein R 1a and R 1b Independently selected from H, C 1-4 Alkyl and C 1-4 Halogenated alkyl.
[0494] 76. The method according to any one of embodiments 71 to 75, wherein R 1a and R 1b It's H.
[0495] 77. The method according to any one of embodiments 71 to 76, wherein R 3 Selected from C 4-6 Cycloalkyl, 5- or 6-membered heterocyclyl, aryl, heteroaryl, alkylaryl and aralkyl.
[0496] 78. The method according to any one of embodiments 71 to 77, wherein R 3 yes
[0497] 79. The method according to any one of embodiments 71 to 78, wherein R 3 yes
[0498] 80. The method of any one of embodiments 71 to 79, wherein q is 0.
[0499] 81. The method according to embodiment 71, wherein the compound of formula (I) or a salt thereof is selected from:
[0500] and salts of any of them.
[0501] 82. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (VI) or a salt thereof:
[0502]
[0503] in:
[0504] R a are each independently selected from alkyl, haloalkyl, alkenyl, haloalkenyl and alkoxy;
[0505] R 1 and R 2 One of is H or alkyl;
[0506] R 1 and R 2 The other one is selected from H, alkyl, alkoxy, -(C1-C6 alkylene)-C(O)NR x1 -(C1-C6 alkylene)-aryl and -(C1-C6 alkylene)-C(O)NR x2 -(C1-C6 alkyl), where R x1 and R x2 are each independently H, alkyl or haloalkyl; and
[0507] p is 0, 1 or 2.
[0508] 83. The method according to embodiment 82, wherein R x1 It's H.
[0509] 84. The method according to embodiment 82 or 83, wherein R x2 It's H.
[0510] 85. The method according to any one of embodiments 82 to 84, wherein R 1 and R 2 One of them is H.
[0511] 86. The method according to embodiment 85, wherein R 1 and R 2 The other one is selected from C1-C6 alkyl,
[0512] 87. The method according to embodiment 85, wherein R 1 and R 2 The other one of which is selected from isopropyl,
[0513] 88. The method of any one of embodiments 82 to 87, wherein p is 0.
[0514] 89. The method of any one of embodiments 82 to 87, wherein p is 1.
[0515] 90. The method according to embodiment 82, wherein R a It is a C1-C6 alkyl group or a C1-C6 alkoxy group.
[0516] 91. The method according to embodiment 82, wherein R a It is a C1-C3 alkyl group or a C1-C3 alkoxy group.
[0517] 92. The method according to any one of embodiments 82 to 91, wherein R a It is -CH3 or -OCH3.
[0518] 93. The method according to embodiment 82, wherein the compound of formula (VI) or a salt thereof is selected from: and salts of any of them.
[0519] 94. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound selected from:
[0520]
[0521]
[0522]
[0523] and salts of any of them.
[0524] 95. The method of any one of embodiments 1 to 94, wherein the subject has been diagnosed with a skin condition, disorder or disease.
[0525] 96. The method of any one of embodiments 1 to 94, wherein the subject has not been diagnosed with a skin condition, disorder or disease.
[0526] 97. The method according to any one of embodiments Error! Reference source not found. to 96, wherein the composition is a pharmaceutical composition.
[0527] 98. The method according to embodiment 97 further comprises at least one additive selected from the group consisting of a pharmaceutically acceptable carrier, an excipient, an adjuvant, a diluent and a combination thereof.
[0528] 99. The method according to any one of embodiments 1 to 96, wherein the composition is a cosmetic composition.
[0529] 100. The method according to embodiment 99, further comprising at least one additive selected from the group consisting of cosmetically acceptable carriers, excipients, adjuvants, diluents and combinations thereof.
[0530] 101. The method according to any one of embodiments 1 to 100, wherein the composition is formulated as a toner, cream, emulsion, lotion, ointment, paste, gel, suspension, serum, oil, spray, emulsion, mousse or mist.
[0531] 102. The method of any one of the preceding embodiments, wherein the administering comprises administering the composition to an area of skin of the subject.
[0532] 103. The method of any of the preceding embodiments, wherein the skin area comprises facial skin, elbow skin, neck skin, hand skin, peri-articular skin, or a combination thereof.
[0533] 104. The method of embodiment 103, wherein the facial skin includes the skin of the forehead, temples, malar area, nasolabial folds, marionette lines, chin, mandible, mid-face, preauricular area, periorbital depressions, cheeks, jawline, lips, or any combination thereof.
[0534] 105. The method according to any one of the preceding embodiments, wherein the method prevents or reduces wrinkles or fine lines.
[0535] 106. The method according to any one of the preceding embodiments, wherein the method increases skin firmness.
[0536] 107. The method according to any one of the preceding embodiments, wherein the method moisturizes / hydrates the skin.
[0537] 108. The method of any one of the preceding embodiments, wherein the method increases skin collagen production or collagen depositing cell proliferation.
[0538] 109. The method of any one of the preceding embodiments, wherein the method increases fibroblast proliferation.
[0539] Example
[0540] The invention now being generally described, it will be more readily understood by reference to the following examples, which are included merely for the purpose of illustrating certain aspects and embodiments of the invention and are not intended to limit the invention in any way.
[0541] Example 1: Human dermal fibroblast (hDFC) proliferation assay
[0542] Use a cell viability assay such as Promega Luminescent cell viability assay, MTT cell proliferation assay ( The ability of the compounds or salts of the present disclosure to increase the proliferation of human dermal fibroblasts was tested by RT-PCR (30-1010K) or manual cell counting. In some cases, the Promega and manual cell counting.
[0543] Compounds or salts were added at different concentrations spanning at least a 2-log range. Fibroblasts were cultured on tissue culture treated plastic using a predefined growth medium (i.e., fibroblast growth medium; Promocell) containing basic fibroblast growth factor (FGFβ). In Table 14, "activity" refers to the percentage (%) of increased hFDPC proliferation. For this activity, "A" represents an increase in hFDPC proliferation of less than 1%, "B" represents an increase in hFDPC proliferation of equal to or greater than 1% and less than 4%, "C" represents an increase in hFDPC proliferation of equal to or greater than 4% and less than 8%, and "D" represents an increase in hFDPC proliferation of equal to or greater than 8%.
[0544] Table 14. Evaluation of small molecules based on hDFC proliferation
[0545]
[0546]
[0547]
[0548] *Control was DMSO.
[0549] Example 2: Assay on human dermal microvascular endothelial cells (HDMEC)
[0550] Use a cell viability assay such as Promega Luminescent cell viability assay, MTT cell proliferation assay ( The ability of the compounds or salts of the present disclosure to affect the proliferation of adult human dermal microvascular endothelial cells was tested after 48 hours (30-1010K) or cell counts. The compounds or salts were added at different concentrations spanning at least a 2-log range.
[0551] Example 3: Keratinocyte assay
[0552] Adult epidermal keratinocytes were cultured on poly-L-lysine treated plates and assayed using a cell viability assay such as the Promega Luminescent cell viability assay, MTT cell proliferation assay ( The ability of the disclosed compounds or salts to affect proliferation was measured after 48 hours (30-1010K) or cell counts. Compounds or salts were added at different concentrations spanning at least a 2-log range.
[0553] Example 4: Determination of primary epidermal melanocytes; normal, human, adult (HEMa)
[0554] Use a cell viability assay such as Promega Luminescent cell viability assay, MTT cell proliferation assay ( The ability of the disclosed compounds or salts to affect the proliferation of adult epidermal melanocytes was tested after 48 hours using a 30-10 log (10-10 k) or cell count. The compounds or salts were added at different concentrations spanning at least a 2-log range. Melanocytes derived from at least two different donors with different degrees of basal skin pigmentation were used.
[0555] Example 5: Safety / toxicology studies on a computer
[0556] The in silico safety / toxicological profiles of compounds were determined by screening chemical structures against a range of computational models. These included the Pred-hERG 4.2 cardiotoxicity model and the NeuroDeRisk ILProfiler neurotoxicity model from the QSAR Toolbox, as well as models for reproductive and developmental toxicity, carcinogenicity (genotoxic and non-genotoxic), skin sensitization, DNA mutation, and chromosome aberration.
[0557] Example 6: Safety / Toxicology Studies
[0558] The safety / toxicological profile of the disclosed compounds or salts was evaluated via a series of in vitro genotoxicity assays (including the SOS-chromogenic assay) for determining bacterial genotoxicity and the TK.6 micronucleus assay for determining chromosomal damage and forward mutations. Standard reactive oxygen species (ROS) and caspase 3 / 7 assays were performed to determine general cytotoxicity. In addition, a series of sensitization tests were performed to predict any potential skin sensitivity. These included direct peptide reactivity assays for evaluating haptenization, KeratinoSens reporter gene assays for determining any potential sensitivity via activation of cytoprotective pathways, and immunological assays using human immature monocyte-derived dendritic cells for evaluating any potential immunogenicity.
[0559] The exemplified compounds showed no genotoxic transformation potential ( Figure 5A-5E ). TK.6 lymphoblastoid cells are a cell line used for gene mutation analysis. TK.6 lymphoblastoid cells are heterozygous for the thymidine kinase gene (TK) and are capable of detecting forward mutations and chromosomal damage, which manifests as micronuclei. TK.6 lymphoblastoid cells can be detected via flow cytometry. TK.6 cells were dosed with compound or vehicle control (0.1% v / v DMSO) and cultured for 24 hours without S9 metabolic activation. Figure 5A-5E Results of an in vitro genotoxicity assay and a TK.6 micronucleus assay are shown. Figure 5A An example of TK.6 cells treated with compound V-1. The genotoxic alkylating agent methyl methanesulfonate was used as a positive control for the micronucleus assay. Figure 5B Shown is the quantification of the TK.6 micronucleus assay following treatment with a range of concentrations of various example compounds. Figure 5C Shown are normalized β-galactosidase activity (as quantified via absorbance) from the SOS chromogenic assay using varying concentrations of genotoxin (4-NQ; 4-nitroquinoline-1-oxide) and example compounds. The SOS chromogenic assay is a bacteria-based genotoxicity test. Figure 5B and Figure 5C The results showed that the exemplary compound V-1 did not show any genotoxic transformation potential, while compounds IV-2, I-1, II-1, III-1 and IV-1 showed mild genotoxicity at higher concentrations. Figure 5D Normalized reactive oxygen species (ROS) activity of human dermal papilla cells treated with 5 μg / mL of example compounds for 24 hours relative to vehicle control (0.1% v / v DMSO) is shown. All example compounds tested induced little or no change in ROS activity compared to baseline vehicle control. Figure 5EShown are normalized caspase 3 / 7 activity in HepG2 cells, an immortalized hepatocyte cell line used to study apoptosis induced by small molecules. Cells were treated with compounds or vehicle control containing the corresponding % v / v matched amount of DMSO. High represents 10 μg / mL and low represents 1 μg / mL. The tested compounds caused no or slight caspase 3 / 7 activation at low and high concentrations. Figure 5A-5E Data are mean ± SD and are representative of at least 2 experimental replicates.
[0560] Further studies will include mechanism-oriented studies, including metabolism and transport studies focusing on the ability of the disclosed compounds or salts to induce or inhibit cytochrome P450, passive / active transport using the Caco-2 cell line (a well-established compound transport assay). Additional safety and toxicity studies include functional cardiotoxicity and neurotoxicity in human iPSC-derived cardiomyocytes and neurons, respectively. Finally, 200 human subjects will be subjected to repeated injury patch testing using the disclosed compounds or salts to predict any possible allergic contact dermatitis and related reactions.
[0561] Example 7: Skin Sensitization Potential or Immunogenicity
[0562] The exemplified compounds did not show any skin sensitization potential or immunogenicity ( Figure 6A-6E ). The Nrf2-ARE pathway is a major regulator of the cytoprotective response to oxidative stress and is an early indicator of skin sensitization. Nrf2 (nuclear factor erythroid 2-related factor) is a transcription factor that binds to the antioxidant response element (ARE). The KeratinoSens Nrf2-ARE reporter gene assay was constructed by fusing the ARE to the luminescent luciferase gene, whereby the luciferase signal is directly correlated with Nrf2-ARE pathway activation. Fig. 6A Normalized ARE-luciferase activity using a range of concentrations of a sensitizing compound (cinnamaldehyde) and exemplary compounds is shown. Compound IV-1 exhibited sensitizing potential, while compounds I-1, II-1, III-1, IV-2, V-1, and VII-34 did not exhibit significant Nrf2-ARE pathway activation. Figure 6B An in vitro dendritic cell sensitization assay is described. Dendritic cell activation is widely associated with downstream immunogenicity. CD14+ cells are harvested from human donor peripheral monocytes and differentiated into immature monocyte-derived DCs using granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4), and then treated with leading compounds. Killed Escherichia coli (E. Coli) and TNF-α are used as positive controls. Figure 6C-Figure 6Eis an example diagram showing changes in HLA-DR expression. Figure 6C )、PDL-1( Fig.6D ) and CD141( Fig. 6E ) expression was quantified via mean fluorescence intensity (MFI) after administration of exemplary compounds. Figure 6C-Figure 6E None of the exemplified compounds showed any mo-DC activation potential. Figure 6A-6E Data are mean ± SD and are representative of at least 2 experimental replicates.
[0563] Example 8: Clinical study
[0564] The clinical trial was conducted by Eurofins|CRL, Inc. The trial followed standardized procedures for the establishment of clinical trials designed to ensure the health of clinical research subjects and the generation of reliable research data. 120 male and female subjects ranging in age from 18 to 70 years old were selected to participate in the study. The purpose of the study was to determine the potential of a test material containing 0.01% v / v of Compound V-1 (in a formulation) to cause skin irritation and / or induce sensitization after repeated patch applications.
[0565] Table 15. Clinical repeated injury patch test using compound V-1
[0566]
[0567] A clinical consumer perception study was conducted using Compound V-1. The third unit (Unit 3) was used to test the general formulation compatibility and irritation of Compound V-1 and low-dose retinol in the formulation. As reported, there were 0 adverse reactions in all units including Unit 3. The test results are shown in Table 16.
[0568] Table 16. Clinical consumer perception study using compound V-1
[0569]
[0570] After 8 weeks, the Canfield Visia-CR system was used to take photos ( Figure 7). The subjects were female and aged 51-70 years. A simple water-based formula containing the exemplary compound V-1 (0.5% w / v) was used. The subjects were instructed to apply the formula 1-2 times a day after cleansing with Cetaphil Daily Cleanser. Sunscreen (Neutrogena Oil-Free Moisturizer SPF 35) was required, and avoidance of direct sunlight was encouraged. The study did not require randomization, and the subjects did not know the names of the test materials. According to the meter readings, the subjects using the formula containing compound V-1 showed a 2-fold improvement in skin elasticity compared to the gold standard 0.5% retinol formula. The side effects reported by the subjects were also relatively few compared to 0.5% retinol.
[0571] A total of 43 healthy female subjects agreed, enrolled and completed the clinical study. In Table 17, Unit 1 represents the participant group using the gold standard 0.5% retinol formula. Unit 2 represents the participant group using a simple water-based formula containing example compound V-1 (0.5% w / v). Unit 3 represents the participant group using a combination formula of example compound V-1 and low-dose retinol (0.3% retinol).
[0572] Table 17. Subject Demographics for Clinical Consumer Perception Study Using Compound V-1
[0573]
[0574]
[0575] Example 9: Efficacy Study
[0576] The functional characteristics of the compounds or salts of the present disclosure continue to be studied in many in vitro models and observational clinical trials. In addition, transcriptomic and proteomic analyses will be performed on the relevant genes and proteins (such as collagen) with recognized effects on cells exposed to the compounds or salts of the present disclosure. The compounds or salts of the present disclosure will be processed on living human skin grafts removed by cosmetic surgery to evaluate the targeted activation of human dermal fibroblasts in histological studies. Additional mechanical tests will be performed, including stiffness and viscoelasticity measurements, to further evaluate the functional benefits of the compounds of the salts of the present disclosure. Finally, clinical efficacy trials will be performed on at least 30 human subjects to determine the effectiveness of the compounds or salts of the present disclosure in improving the appearance of skin tightening. Additional trials with more subjects and across a wider range of age groups and population characteristics may then be performed.
[0577] Example 10: Mechanism Analysis
[0578] Using the transcriptomic dataset, a series of mechanistic computational analyses will be performed to identify possible mechanisms of action. These may include DE analysis followed by GO terms and pathway enrichment to characterize the biosignature of our lead chemicals. In addition, pseudo-time and cell cycle analyses will be performed to probe the developmental effects of these chemicals on target cells. The insights extracted in further studies will be validated using different models.
[0579] Example 11: Synthesis of Compound V-1
[0580]
[0581] Solution 1
[0582] Step A: Compound 1 (20 g, 0.2 mol) was dissolved in 150 ml of dichloromethane and compound 2 (34.3 g, 0.2 mol) was added. The mixture was shaken vigorously for 12 hours. The solvent was evaporated in vacuo. 150 ml of n-hexane was added to the remaining solid and the mixture was shaken vigorously for 20 minutes. The solvent was poured out from the solid residue and the solid was dried in vacuo. Yield: 43 g.
[0583] Step B: at room temperature to the solution of compound 3 (43g, 0.15mol) in MeOH (155ml), add the aqueous solution of 1M KOH (2eq). Make the reaction mixture reflux, until the starting material is completely consumed as monitored by liquid chromatography mass spectrum (LCMS). By water layer CH2Cl2 (300ml) washing, then acidify to pH 2 with concentrated HCl to obtain solid precipitate, collect this solid precipitate by filtration. Precipitate is thoroughly washed with water (3x100 ml), to obtain product. Output is 32g.
[0584] Example 12: Synthesis of Compound IV-2
[0585]
[0586] Solution 2
[0587] Step A: Compound 2 (20 g, 0.1 mol) was dissolved in 150 ml of acetonitrile and NaHCO (0.2 mol) was added. The mixture was stirred at room temperature for 30 minutes and compound 1 (12.4 g, 0.11 mol) was added. The reaction mixture was stirred at room temperature for 12 h (thin layer chromatography and LCMS comparison), the solvent was evaporated in vacuo, and 150 ml of water was added at 10 ° C. The precipitate was filtered, washed with cold water (3x100 ml) and dried in vacuo for 10 h. The yield was 9.8 g.
[0588] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Without departing from the present invention, those skilled in the art will now conceive of many variations, changes and replacements. It should be understood that the various alternatives of the embodiments of the present invention described herein can be used to practice the present invention. The following claims are intended to define the scope of the present invention, and thus cover methods and structures and their equivalents within the scope of these claims.
Claims
1. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of formula (V) or a salt thereof: in: Y 1 O, S or NR 1 , where R 1 is H, alkyl or haloalkyl; R 2 is selected from the group consisting of H, alkyl, haloalkyl, alkenyl, haloalkenyl, aryl, and aralkyl; and R 3 Selected from H, alkyl, haloalkyl, -(CH2) m1 -OR a1 、-(CH2) m2 -O-(CH2) m3 -OR a2 、-(CH2) m4 -NR b1 R b2 、(CH2) m5 -C(O)OR c ,in: R a1 , R a2 , R b1 , R b2 and R c are each independently selected from H, alkyl and haloalkyl; and m1, m2, m3, m4 and m5 are each independently selected from 1, 2, 3 and 4.
2. The method according to claim 1, wherein Y 1 It is O or S.
3. The method according to claim 1, wherein Y 1 It's O.
4. The method according to claim 1, wherein R a1 , R a2 , R b1 , R b2 and R c Each is independently a C1-C6 alkyl group.
5. The method according to claim 1, wherein R a1 , R a2 , R b1 , R b2 and R c Each is independently a C1-C3 alkyl group.
6. The method according to claim 5, wherein R a1 , R a2 , R b1 , R b2 and R c Each is independently a C1 alkyl group or a C2 alkyl group.
7. The method according to claim 1, wherein m1, m2, m3 and m4 are each independently 2 or 3. The method according to claim 1 , wherein m5 is 1.
9. The method according to claim 1, wherein R 2 It's H.
10. The method according to claim 1, wherein the compound of formula (V) or the salt thereof is selected from: and salts of any of them.
11. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (IV) or a salt thereof: in: R 1 is selected from alkyl or heterocycloalkyl, wherein R 1 The alkyl or heterocycloalkyl of is optionally independently selected from heterocycloalkyl, -C(O)NR x1 R x2 , alkoxy, -(C1-C3 alkylene)-C(O)OR y1 、-C(O)OR y2 AND-OR z substituted with one or more substituents; wherein: R x1 , R x2 , R y1 , R y2 and R z are each independently selected from H, alkyl and haloalkyl; R A is H or alkyl; X is -O-, -S- or -NR B -; R B is H, alkyl or haloalkyl; R 2 and R 3 are each independently selected from H, linear C1-C6 alkyl, branched C1-C6 alkyl; or alternatively, R 2 and R 3 together with the atoms to which they are attached to form a C4-C6 cycloalkyl or aryl group, wherein the cycloalkyl or aryl group is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl; and The dashed lines indicate the presence of single or double bonds.
12. The method according to claim 11, wherein the compound of formula (IV) has the structural formula:
13. The method according to claim 12, wherein the compound of formula (IV) has the structural formula:
14. The method according to claim 11, wherein the compound of formula (IV) has the structural formula:
15. The method according to claim 14, wherein the compound of formula (IV) has the structural formula:
16. The method according to claim 11, wherein R 2 and R 3 Each is independently selected from C1-C6 alkyl.
17. The method according to claim 11, wherein R 2 and R 3 Together with the atoms to which they are attached to form a C4-C6 cycloalkyl group optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl.
18. The method according to claim 17, wherein R 2 and R 3 Together with the atoms to which they are attached to form a cyclohexyl group, the cyclohexyl group is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl.
19. The method according to claim 11, wherein R 2 and R 3 Together with the atoms to which they are attached, they form C 5-8 Aryl, the C 5-8The aryl group is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl.
20. The method according to claim 19, wherein R 2 and R 3 Together with the atoms to which they are attached to form a phenyl group, the phenyl group is optionally substituted with one or more substituents independently selected from halogen, alkyl and haloalkyl.
21. The method according to claim 11, wherein R A It's H.
22. The method of claim 11, wherein X is -O-.
23. The method of claim 11, wherein X is -NR B -, optionally, wherein R B It's H.
24. The method according to claim 11, wherein R 1 Selected from: -(CH2) a C(O)OH, -(CH2) a OCH3, -(CH2) a CH(OH)CH3, in: a is 0, 1, 2, or 3.
25. The method according to claim 11, wherein R 1 Selected from: -CH2C(O)OH, -(CH2)2OCH3, -CH2CH(OH)CH3, 26. The method according to claim 11, wherein R x1 and R x2 Each is independently a C1-C6 alkyl group.
27. The method according to claim 11, wherein R x1 and R x2 Each is independently a C1-C3 alkyl group.
28. The method according to claim 11, wherein R y1 It's H.
29. The method according to claim 11, wherein R y2 It's H.
30. The method according to claim 11, wherein R z It's H.
31. The method according to claim 11, wherein the compound of formula (IV) or the salt thereof is selected from: and salts of any of them.
32. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (VII) or a salt thereof: in: A is selected from O, NH, S; R 1 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 2-10 Alkynyl, C 3-12 Carbocyclic and 3- to 12-membered heterocyclic rings; R 2 is selected from a 6- to 10-membered heterocyclic ring, wherein the 6- to 10-membered heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, -OR 11 、-SR 11 , -NO2, =O, =NH, -CN, -C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2.-NR 11 S(O)2R 11 、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )C(O)OR 11 、-S(O)2(R 11 )、-S(O)2N(R 11 2. C 1-10 Alkyl, C3-C 12 Carbocyclic and 5- to 12-membered heterocyclic rings; n is selected from 1, 2, 3, 4, 5 and 6; Each R 11 is independently selected at each occurrence from hydrogen; C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-12 carbocyclic rings, each of which is optionally substituted with one or more substituents selected from 3- to 6-membered heterocyclic rings.
33. The method of claim 32, wherein A is O.
34. The method of claim 32, wherein R 1 It is C 1-6 alkyl.
35. The method of claim 34, wherein R 1 It is a C1 alkyl group.
36. The method of claim 32, wherein n is selected from 1 and 3.
37. The method of claim 36, wherein n is 1.
38. The method of claim 37, wherein n is 3.
39. The method of claim 32, wherein R 2 The 6- to 10-membered heterocyclic ring is selected from pyran, pyridine, piperidine, imidazole, thiazole, dioxane, morpholine, pyrimidine, benzimidazole, piperazine, thiadiazine, oxepane, thiene, azoctatetraene, indole, isoindole, indolizine, quinoline, isoquinoline, purine, carbazole and dibenzofuran.
40. The method of claim 39, wherein R 2 Selected from benzimidazole and piperazine.
41. The method of claim 40, wherein R 2 yes 42. The method of claim 40, wherein R 2 It's piperazine.
43. The method of claim 42, wherein piperazine is optionally independently selected from ═O and —C(O)R 11 is substituted with one or more substituents.
44. The method of claim 32, wherein R 11 is C substituted by one or more substituents selected from 3- to 6-membered heterocyclic rings1-6 alkyl.
45. The method of claim 44, wherein C 1-6 The alkyl group is a C1 alkyl group or a C2 alkyl group.
46. according to the method for claim 44 or 45, wherein said 3- to 6-membered heterocycle is 47. The method of claim 32, wherein each R 2 Selected from:
48. The method of claim 32, wherein the compound of formula (VII) or the salt thereof is selected from: and salts of any of them.
49. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (III) or a salt thereof: in: L 1 , L 2 and L 3 Each independently selected from a bond, a straight chain C 1-6 Alkyl or branched C 1-6 alkyl; A is N-amido, -NH-C(O)- or -C(O)-NH-; Ring B is selected from C 4-6 Cycloalkyl, 5- or 6-membered heterocyclic group, C 5-8 Aryl, heteroaryl and aralkyl groups; R x and R y Each is independently selected from halogen, alkyl, haloalkyl, alkenyl, haloalkenyl, hydroxy, alkoxy, haloalkoxy, nitro, -NH2, alkylamino, dialkylamino and haloalkylamino; m is 0, 1, or 2; and n is 0 or 1.
50. The method according to claim 49, wherein ring B is selected from C 5-8 Aryl, heteroaryl and aralkyl.
51. The method according to claim 49, wherein ring B is selected from C 5-8 Aryl and heteroaryl groups.
52. The method of claim 51, wherein C 5-8 Aryl is phenyl and heteroaryl is imidazolyl.
53. The method of claim 49, wherein R x It is a C1-C3 alkoxy group.
54. The method of claim 53, wherein R x It is -OCH3.
55. The method of claim 49, wherein Ring B is 56. The method of claim 49, wherein Ring B is 57. The method of claim 49, wherein m is 0 or 1.
58. The method of claim 49, wherein n is 0.
59. The method of claim 49, wherein the compound of formula (III) or the salt thereof is selected from: and salts of any of them.
60. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (II) or a salt thereof: in: R 1a and R 1b are each independently selected from H, alkyl, haloalkyl, alkenyl, haloalkenyl, C 5-8 Aryl and aralkyl groups; R x are each independently selected from halogen, alkyl, haloalkyl, alkenyl, haloalkenyl, -OH, alkoxy, haloalkoxy, nitro, -NH2, alkylamino, dialkylamino, and haloalkylamino; p is 1, 2, or 3; q is 0, 1, or 2; R 2 is selected from the group consisting of H, alkyl, alkenyl, haloalkyl, haloalkenyl, nitro, -NH2, alkylamino, dialkylamino, alkyl-dialkylamino, and haloalkylamino; and R 3 is selected from H, alkyl and haloalkyl.
61. The method of claim 60, wherein R 1a and R 1b Independently selected from H and C 1-6 alkyl.
62. The method of claim 60, wherein R 1a and R 1b It's H.
63. The method of claim 60, wherein R x It is a C1 to C6 alkoxy group.
64. The method of claim 62, wherein R x It is -OCH3.
65. The method of claim 60, wherein q is 0 or 1.
66. The method of claim 60, wherein p is 1.
67. The method of claim 60, wherein R 2 It is C 1-6 Alkyl, alkyl-di(C1-C6)alkylamino, mono-(C1-C6)alkylamino and di(C1-C6)alkylamino.
68. The method of claim 60, wherein R 2is selected from methyl, ethyl, propyl, butyl, isopropyl, isobutyl and 69. The method of claim 60, wherein R 3 It's H.
70. The method according to claim 60, wherein the compound of formula (II) or the salt thereof is selected from: and salts of any of them.
71. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (I) or a salt thereof: in: R 1a and R 1b independently selected from H, alkyl and haloalkyl; R 3 is selected from the group consisting of cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl or aralkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, alkyl, alkoxy and haloalkoxy; R x are each independently selected from halogen, alkyl, haloalkyl, alkenyl, haloalkenyl, -OH, alkoxy, haloalkoxy, -NH2, alkylamino, dialkylamino, and haloalkylamino; p is 1, 2, or 3; q is 0, 1, or 2; and Q is selected from O, S and NR 2 , where R 2 is selected from the group consisting of H, alkyl, alkenyl, haloalkyl, haloalkenyl, nitro, -NH2, alkylamino, dialkylamino and haloalkylamino.
72. The method of claim 71, wherein Q is NR 2 .
73. The method of claim 71, wherein R 2 Selected from amino, C 1-3 Alkyl and C 1-3 Alkenyl.
74. The method of claim 71, wherein R 1a and R 1b Independently selected from H, C 1-6 Alkyl and C 1-6 Halogenated alkyl.
75. The method of claim 71, wherein R 1a and R 1b Independently selected from H, C 1-4 Alkyl and C 1-4 Halogenated alkyl.
76. The method of claim 71, wherein R 1a and R 1b It's H.
77. The method of claim 71, wherein R 3 Selected from C 4-6 Cycloalkyl, 5- or 6-membered heterocyclyl, aryl, heteroaryl, alkylaryl and aralkyl.
78. The method of claim 71, wherein R 3 yes 79. The method of claim 78, wherein R 3 yes 80. The method of claim 71, wherein q is 0.
81. The method of claim 71, wherein the compound of formula (I) or the salt thereof is selected from: and salts of any of them.
82. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound having a structure of Formula (VI) or a salt thereof: in: R a are each independently selected from alkyl, haloalkyl, alkenyl, haloalkenyl and alkoxy; R 1 and R 2 One of is H or alkyl; R 1 and R 2 The other one is selected from H, alkyl, alkoxy, -(C1-C6 alkylene)-C(O)NR x1 -(C1-C6 alkylene)-aryl and -(C1-C6 alkylene)-C(O)NR x2 -(C1-C6 alkyl), where R x1 and R x2 are each independently H, alkyl or haloalkyl; and p is 0, 1 or 2.
83. The method of claim 82, wherein R x1 It's H.
84. The method of claim 82, wherein R x2 It's H.
85. The method of claim 82, wherein R 1 and R 2 One of them is H.
86. The method of claim 85, wherein R 1 and R 2 The other one is selected from C1-C6 alkyl, 87. The method of claim 85, wherein R 1 and R 2 The other one of which is selected from isopropyl, 88. The method of claim 82, wherein p is 0.
89. The method of claim 82, wherein p is 1.
90. The method of claim 82, wherein R a It is a C1-C6 alkyl group or a C1-C6 alkoxy group.
91. The method of claim 82, wherein R a It is a C1-C3 alkyl group or a C1-C3 alkoxy group.
92. The method of claim 82, wherein R a It is -CH3 or -OCH3.
93. The method of claim 82, wherein the compound of formula (VI) or the salt thereof is selected from: and salts of any of them.
94. A method for preventing or treating a skin condition, disorder or disease, the method comprising administering to a subject in need thereof a composition comprising a compound selected from: and salts of any of them.
95. The method of claim 94, wherein the subject has been diagnosed with the skin condition, disorder or disease.
96. The method of claim 94, wherein the subject has not been diagnosed with the skin condition, disorder or disease.
97. The method of claim 94, wherein the composition is a pharmaceutical composition.
98. The method of claim 97, further comprising at least one additive selected from the group consisting of a pharmaceutically acceptable carrier, an excipient, an adjuvant, a diluent, and combinations thereof.
99. The method of claim 94, wherein the composition is a cosmetic composition.
100. The method of claim 99, further comprising at least one additive selected from the group consisting of cosmetically acceptable carriers, excipients, adjuvants, diluents, and combinations thereof.
101. The method of claim 94, wherein the composition is formulated as a toner, cream, emulsion, lotion, ointment, paste, gel, suspension, serum, oil, spray, lotion, mousse, or mist.
102. The method of claim 94, wherein the administering comprises administering the composition to an area of skin of the subject.
103. The method of claim 94, wherein the skin area comprises facial skin, elbow skin, neck skin, hand skin, peri-articular skin, or a combination thereof.
104. The method of claim 103, wherein the facial skin comprises skin of the forehead, temples, malar region, nasolabial folds, marionette lines, chin, mandible, mid-face, preauricular region, periorbital recesses, cheeks, jawline, lips, or any combination thereof.
105. The method of claim 94, wherein the method prevents or reduces wrinkles or fine lines.
106. The method of claim 94, wherein the method increases skin firmness.
107. The method of claim 94, wherein the method moisturizes / hydrates the skin.
108. The method of claim 94, wherein the method increases skin collagen production or collagen depositing cell proliferation.
109. The method of claim 94, wherein the method increases fibroblast proliferation.
